| |
|
- Click on the title
of each paper to access MedLine abstract at NLM site Infliximab Dependency in Children with Crohn's Disease. Duricova D, Pedersen N, Lenicek M, Hradsky O, Bronsky J, Adamcova M, Elkjaer M, Andersen PS, Vitek L, Larsen K, Lukas M, Nevoral J, Wewer V, Munkholm P. Aliment Pharmacol Ther. 2009 Jan 13. Systematic review: the efficacy and safety of certolizumab pegol in Crohn's disease. Shao LM, Chen MY, Chen QY, Cai JT. Aliment Pharmacol Ther. 2009 Jan 13. Confirmation of Multiple Crohn's Disease Susceptibility Loci in a Large Dutch-Belgian Cohort. Weersma RK, Stokkers PC, Cleynen I, Wolfkamp SC, Henckaerts L, Schreiber S, Dijkstra G, Franke A, Nolte IM, Rutgeerts P, Wijmenga C, Vermeire S. Am J Gastroenterol. 2009 Jan 27. Effects of active and passive smoking on disease course of Crohn's disease and ulcerative colitis. van der Heide F, Dijkstra A, Weersma RK, Albersnagel FA, van der Logt EM, Faber KN, Sluiter WJ, Kleibeuker JH, Dijkstra G. Inflamm Bowel Dis. 2009 Jan 23. Budesonide for maintenance of remission in Crohn's disease. Benchimol EI, Seow CH, Otley AR, Steinhart AH. Cochrane Database Syst Rev. 2009 Jan 21;(1):CD002913. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Prefontaine E, Sutherland LR, Macdonald JK, Cepoiu M. Cochrane Database Syst Rev. 2009 Jan 21;(1):CD000067. [Adalimumab induction and maintenance therapy for Crohn s disease. An open-label study] López Palacios N, Mendoza JL, Taxonera C, Lana R, Fuentes Ferrer M, Díaz-Rubio M. Rev Esp Enferm Dig. 2008 Nov;100(11):676-81. Spanish Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Burmester GR, Mease PJ, Dijkmans BA, Gordon K, Lovell D, Panaccione R, Perez J, Pangan AL. Ann Rheum Dis. 2009 Jan 15. Is there a link between food and intestinal microbes and the occurrence of Crohn's disease and ulcerative colitis? Asakura H, Suzuki K, Kitahora T, Morizane T. J Gastroenterol Hepatol. 2008 Dec;23(12):1794-801. Long-term outcome of maintenance infliximab therapy in children with Crohn's disease. Hyams JS, Lerer T, Griffiths A, Pfefferkorn M, Kugathasan S, Evans J, Otley A, Carvalho R, Mack D, Bousvaros A, Rosh J, Mamula P, Kay M, Crandall W, Oliva-Hemker M, Keljo D, Leleiko N, Markowitz J; for the Pediatric Inflammatory Bowel Disease Collaborative Research Group. Inflamm Bowel Dis. 2008 Dec 23. Polymorphism of the IRGM gene might predispose to fistulizing behavior in Crohn's disease. Latiano A, Palmieri O, Cucchiara S, Castro M, D'Incà R, Guariso G, Dallapiccola B, Valvano MR, Latiano T, Andriulli A, Annese V. Am J Gastroenterol. 2009 Jan;104(1):110-6. Barrier dysfunction due to distinct defensin deficiencies in small intestinal and colonic Crohn's disease. Wehkamp J, Koslowski M, Wang G, Stange EF. Mucosal Immunol. 2008 Nov;1 Suppl 1:S67-74. Review. The molecular basis of NOD2 susceptibility mutations in Crohn's disease. Strober W, Kitani A, Fuss I, Asano N, Watanabe T. Mucosal Immunol. 2008 Nov;1 Suppl 1:S5-9. Review. Perianal disease predicts changes in Crohn's disease phenotype-results of a population-based study of inflammatory bowel disease phenotype. Tarrant KM, Barclay ML, Frampton CM, Gearry RB. Am J Gastroenterol. 2008 Dec;103(12):3082-93. Immune-mediated myositis in Crohn's disease. Shimoyama T, Tamura Y, Sakamoto T, Inoue K. Muscle Nerve. 2009 Jan;39(1):101-5. Systematic review: does concurrent therapy with 5-ASA and immunomodulators in inflammatory bowel disease improve outcomes? ndrews JM, Travis SP, Gibson PR, Gasche C. Aliment Pharmacol Ther. 2009 Mar 1;29(5):459-69. Effects of light smoking consumption on the clinical course of Crohn's disease. Seksik P, Nion-Larmurier I, Sokol H, Beaugerie L, Cosnes J. Inflamm Bowel Dis. 2008 Dec 9. Upper gastrointestinal tract phenotype of Crohn's disease is associated with early surgery and further hospitalization. Chow DK, Sung JJ, Wu JC, Tsoi KK, Leong RW, Chan FK. Inflamm Bowel Dis. 2008 Dec 9. Adalimumab for Crohn's disease with intolerance or lost response to infliximab: a 3-year single-centre experience. Oussalah A, Babouri A, Chevaux JB, Stancu L, Trouilloud I, Bensenane M, Boucekkine T, Bigard MA, Peyrin-Biroulet L. Aliment Pharmacol Ther. 2009 Feb 15;29(4):416-23. Oral budesonide for maintenance of remission of Crohn's disease: a pooled safety analysis. Lichtenstein GR, Bengtsson B, Hapten-White L, Rutgeerts P. Aliment Pharmacol Ther. 2008 Nov 13 Infliximab treatment for symptomatic Crohn's disease strictures. Pelletier AL, Kalisazan B, Wienckiewicz J, Bouarioua N, Soulé JC. Aliment Pharmacol Ther. 2009 Feb 1;29(3):279-85. The safety profile of anti-TNF therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up. Lees CW, Ali A, Thompson AI, Ho GT, Forsythe RO, Marquez L, Cochrane CJ, Aitken S, Fennell J, Rogers P, Shand AG, Penman ID, Palmer KR, Wilson DC, Arnott ID, Satsangi J. Aliment Pharmacol Ther. 2008 Nov 4. Predicting Factors of Fistula Healing and Clinical Remission After Infliximab-Based Combined Therapy for Perianal Fistulizing Crohn's Disease. Tougeron D, Savoye G, Savoye-Collet C, Koning E, Michot F, Lerebours E. Dig Dis Sci. 2008 Nov 12. Crohn's disease evaluated with magnetic resonance enteroclysis: diagnostic performance of experienced and inexperienced readers before and after training. Negaard A, Mulahasanovic A, Reisaeter LA, Aasekjaer K, Sandvik L, Klow NE. Acta Radiol. 2008 Nov;49(9):967-74. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. Loftus EV, Feagan BG, Colombel JF, Rubin DT, Wu EQ, Yu AP, Pollack PF, Chao J, Mulani P. Am J Gastroenterol. 2008 Dec;103(12):3132-41. Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. Treton X, Bouhnik Y, Mary JY, Colombel JF, Duclos B, Soule JC, Lerebours E, Cosnes J, Lemann M; Groupe D'Etude Thérapeutique Des Affections Inflammatoires Du Tube Digestif (GETAID). Clin Gastroenterol Hepatol. 2009 Jan;7(1):80-5. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Feagan BG, Panaccione R, Sandborn WJ, D'Haens GR, Schreiber S, Rutgeerts PJ, Loftus EV Jr, Lomax KG, Yu AP, Wu EQ, Chao J, Mulani P. Gastroenterology. 2008 Nov;135(5):1493-9. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Caspersen S, Elkjaer M, Riis L, Pedersen N, Mortensen C, Jess T, Sarto P, Hansen TS, Wewer V, Bendtsen F, Moesgaard F, Munkholm P; Danish Crohn Colitis Database. Clin Gastroenterol Hepatol. 2008 Nov;6(11):1212-7; quiz 1176. Long-term outcome of treatment with infliximab in 614 Crohn's disease patients: results from a single centre cohort. Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, VAN Assche G, Hoffman I, Van Steen K, Vermeire S, Rutgeerts PJ. Gut. 2008 Nov 18. Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease. Thia KT, Sandborn WJ, Lewis JD, Loftus EV Jr, Feagan BG, Steinhart AH, Hanauer SB, Persson T, Sands BE. Am J Gastroenterol. 2008 Dec;103(12):3123-31.. Budesonide induction and maintenance therapy for Crohn's disease during pregnancy. Beaulieu DB, Ananthakrishnan AN, Issa M, Rosenbaum L, Skaros S, Newcomer JR, Kuhlmann RS, Otterson MF, Emmons J, Knox J, Binion DG. Inflamm Bowel Dis. 2009 Jan;15(1):25-8. Thia KT, Mahadevan U, Feagan BG, Wong C, Cockeram A, Bitton A, Bernstein CN, Sandborn WJ. Inflamm Bowel Dis. 2009 Jan;15(1):17-24. Meijer MJ, Mieremet-Ooms MA, Sier CF, van Hogezand RA, Lamers CB, Hommes DW, Verspaget HW. Inflamm Bowel Dis. 2009 Jan;15(1):84-92. Henriksen M, Jahnsen J, Lygren I, Stray N, Sauar J, Vatn MH, Moum B; IBSEN Study Group. Gut. 2008 Nov;57(11):1518-23. Clinical and molecular characteristics of isolated colonic Crohn's disease. Hancock L, Beckly J, Geremia A, Cooney R, Cummings F, Pathan S, Guo C, Warren BF, Mortensen N, Ahmad T, Jewell D. Inflamm Bowel Dis. 2008 Dec;14(12):1667-77. Malagò R, Manfredi R, Benini L, D'Alpaos G, Mucelli RP. Abdom Imaging. 2008 Nov-Dec;33(6):669-75. The effect of tacrolimus (FK-506) on Japanese patients with refractory Crohn's disease. Tamaki H, Nakase H, Matsuura M, Inoue S, Mikami S, Ueno S, Uza N, Kitamura H, Kasahara K, Chiba T. J Gastroenterol. 2008;43(10):774-9. Is there an association between intestinal perfusion and Crohn's disease activity? A feasibility study using contrast-enhanced ultrasound. Kumar P, Domjan J, Bhandari P, Ellis R, Higginson A. Br J Radiol. 2008 Oct 27. Quality of life of patients and medical cost of "half elemental diet" as maintenance therapy for Crohn's disease: Secondary outcomes of a randomised controlled trial. Takagi S, Utsunomiya K, Kuriyama S, Yokoyama H, Takahashi S, Umemura K, Iwabuchi M, Takahashi H, Takahashi S, Kinouchi Y, Hiwatashi N, Funayama Y, Sasaki I, Tsuji I, Shimosegawa T. Dig Liver Dis. 2008 Oct 20. Immune response and gene polymorphism profiles in Crohn's disease and ulcerative colitis. Queiroz DM, Oliveira AG, Saraiva IE, Rocha GA, Rocha AM, das Graças Pimenta Sanna M, Guerra JB, Dani R, de Lourdes Abreu Ferrari M, Castro LP. Inflamm Bowel Dis. 2008 Oct 22 Effects of Adalimumab Maintenance Therapy on Health-Related Quality of Life of Patients With Crohn's Disease: Patient-Reported Outcomes of the CHARM Trial. Loftus EV, Feagan BG, Colombel JF, Rubin DT, Wu EQ, Yu AP, Pollack PF, Chao J, Mulani P. Am J Gastroenterol. 2008 Oct 3. Azathioprine Withdrawal in Patients With Crohn's Disease Maintained on Prolonged Remission: A High Risk of Relapse. Treton X, Bouhnik Y, Mary JY, Colombel JF, Duclos B, Soule JC, Lerebours E, Cosnes J, Lemann M; Groupe D'Etude ThÉRapeutique Des Affections Inflammatoires Du Tube Digestif (GETAID). Clin Gastroenterol Hepatol. 2008 Sep 4. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Feagan BG, Panaccione R, Sandborn WJ, D'Haens GR, Schreiber S, Rutgeerts PJ, Loftus EV Jr, Lomax KG, Yu AP, Wu EQ, Chao J, Mulani P. Gastroenterology. 2008 Nov;135(5):1493-9. Familial clustering of Crohn's disease in Israel: Prevalence and association with disease severity. Ben-Horin S, Avidan B, Yanai H, Lang A, Chowers Y, Bar-Meir S. Inflamm Bowel Dis. 2008 Oct 6. Molecular prediction of disease risk and severity in a large Dutch Crohn's disease cohort. Weersma RK, Stokkers PC, van Bodegraven AA, van Hogezand RA, Verspaget HW, de Jong DJ, van der Woude CJ, Oldenburg B, Linskens R, van der Steege G, Festen EA, Hommes DW, Crusius JB, Wijmenga C, Nolte IM, Dijkstra G. Gut. 2008 Sep 29. Defining the Optimal Response Criteria for the Crohn's Disease Activity Index for Induction Studies in Patients With Mildly to Moderately Active Crohn's Disease. Thia KT, Sandborn WJ, Lewis JD, Loftus Jr EV, Feagan BG, Steinhart AH, Hanauer SB, Persson T, Sands BE. Am J Gastroenterol. 2008 Sep 11. Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response. González-Lama Y, López-San Román A, Marín-Jiménez I, Casis B, Vera I, Bermejo F, Pérez-Calle JL, Taxonera C, Martínez-Silva F, Menchén L, Martínez-Montiel P, Calvo M, Carneros JA, López P, Mendoza JL, Milicua JM, Huerta A, Sánchez F, Abreu L, López-Palacios N, Maté J, Gisbert JP; Group for the Study of Inflammatory Bowel Diseases from Madrid (ENICMAD). Gastroenterol Hepatol. 2008 Aug-Sep;31(7):421-6. Manipulation of intestinal microbial flora for therapeutic benefit in inflammatory bowel diseases: review of clinical trials of probiotics, pre-biotics and synbiotics. Heilpern D, Szilagyi A. Rev Recent Clin Trials. 2008 Sep;3(3):167-84. Review. The risk of developing Crohn's disease after an appendectomy: a meta-analysis. Kaplan GG, Jackson T, Sands BE, Frisch M, Andersson RE, Korzenik J. Am J Gastroenterol. 2008 Nov;103(11):2925-31. The effect of smoking after surgery for Crohn's disease: a meta-analysis of observational studies. Reese GE, Nanidis T, Borysiewicz C, Yamamoto T, Orchard T, Tekkis PP. Int J Colorectal Dis. 2008 Dec;23(12):1213-21. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. D'Haens GR, Vermeire S, Van Assche G, Noman M, Aerden I, Van Olmen G, Rutgeerts P. Gastroenterology. 2008 Oct;135(4):1123-9. Proteomics for prediction and characterization of response to infliximab in Crohn's disease: a pilot study. Meuwis MA, Fillet M, Lutteri L, Marée R, Geurts P, de Seny D, Malaise M, Chapelle JP, Wehenkel L, Belaiche J, Merville MP, Louis E. Clin Biochem. 2008 Aug;41(12):960-7. Small bowel adenocarcinoma in Crohn's disease. Feldstein RC, Sood S, Katz S.Inflamm Bowel Dis. 2008 Aug;14(8):1154-7. Review. A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease. Rahimi R, Nikfar S, Rahimi F, Elahi B, Derakhshani S, Vafaie M, Abdollahi M. Dig Dis Sci. 2008 Sep;53(9):2524-31. Vernier-Massouille G, Balde M, Salleron J, Turck D, Dupas JL, Mouterde O, Merle V, Salomez JL, Branche J, Marti R, Lerebours E, Cortot A, Gower-Rousseau C, Colombel JF. Natural History of Pediatric Crohn's Disease: A Population-Based Cohort Study. Gastroenterology. 2008 Jul 3.
Stolfi C,
Pellegrini R, Franze E, Pallone F, Monteleone G.
Molecular basis of the potential
of mesalazine to prevent colorectal cancer. World J Gastroenterol. 2008 Jul
28;14(28): Smith PA. Nutritional therapy for active Crohn's disease. World J Gastroenterol. 2008 Jul 21;14(27):4420-3. Zvidi I, Hazazi R, Birkenfeld S, Niv Y. The Prevalence of Crohn's Disease in Israel: A 20-Year Survey. Dig Dis Sci. 2008 Jul 24. Butterworth AD, Thomas AG, Akobeng AK.Probiotics for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2008 Jul 16;(3):CD006634. Review. Seow CH, Benchimol EI, Griffiths AM, Otley AR, Steinhart AH.Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2008 Jul 16;(3):CD000296. Review. Nguyen GC, Steinhart AH.Nationwide patterns of hospitalizations to centers with high volume of admissions for inflammatory bowel disease and their impact on mortality. Inflamm Bowel Dis. 2008 Jul 11. McGuckin MA, Eri R, Simms LA, Florin TH, Radford-Smith G.Intestinal barrier dysfunction in inflammatory bowel diseases. Inflamm Bowel Dis. 2008 Jul 11. Jones J, Panaccione R.Biologic therapy in Crohn's disease: state of the art. Curr Opin Gastroenterol. 2008 Jul;24(4):475-81. Peyrin-Biroulet L, Desreumaux P, Sandborn WJ, Colombel JF.Crohn's disease: beyond antagonists of tumour necrosis factor. Lancet. 2008 Jul 5;372(9632):67-81. Review. Biancone L, Onali S, Calabrese E, Petruzziello C, Zorzi F, Condino G, Sica GS, Pallone F.Non-invasive techniques for assessing postoperative recurrence in Crohn's disease. Dig Liver Dis. 2008 Jul;40 Suppl 2:S265-70. Wiese DM, Rivera R, Seidner DL.Is there a role for bowel rest in nutrition management of Crohn's disease? Nutr Clin Pract. 2008 Jun-Jul;23(3):309-17. Palamaras I, El-Jabbour J, Pietropaolo N, Thomson P, Mann S, Robles W, Stevens H.Metastatic Crohn's disease: a review. J Eur Acad Dermatol Venereol. 2008 Jun 19 Henriksen M, Jahnsen J, Lygren I, Stray N, Sauar J, Vatn MH, Moum B.C -Reactive Protein: A Predictive Factor And Marker Of Inflammation In Inflammatory Bowel Disease Results From A Prospective Population-Based Study. Gut. 2008 Jun 19 Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF.Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008 Jun;6(6):644-53. Efthymiou A, Viazis N, Mantzaris G, Papadimitriou N, Tzourmakliotis D, Raptis S, Karamanolis DG.Does clinical response correlate with mucosal healing in patients with Crohn's disease of the small bowel? A prospective, case-series study using wireless capsule endoscopy. Inflamm Bowel Dis. 2008 Jun 2. Hancock L, Beckly J, Geremia A, Cooney R, Cummings F, Pathan S, Guo C, Warren BF, Mortensen N, Ahmad T, Jewell D.Clinical and molecular characteristics of isolated colonic Crohn's disease. Inflamm Bowel Dis. 2008 Jun 2. Solem CA, Loftus EV Jr, Fletcher JG, Baron TH, Gostout CJ, Petersen BT, Tremaine WJ, Egan LJ, Faubion WA, Schroeder KW, Pardi DS, Hanson KA, Jewell DA, Barlow JM, Fidler JL, Huprich JE, Johnson CD, Harmsen WS, Zinsmeister AR, Sandborn WJ.Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial. Gastrointest Endosc. 2008 Aug;68(2):255-66. Hadithi M, Cazemier M, Meijer GA, Bloemena E, Felt-Bersma RJ, Mulder CJ, Meuwissen SG, Pena AS, van Bodegraven AA.Retrospective analysis of old-age colitis in the Dutch inflammatory bowel disease population. World J Gastroenterol. 2008 May 28;14(20):3183-7. Stengel JZ, Arnold HL.Is infliximab safe to use while breastfeeding? World J Gastroenterol. 2008 May 21;14(19):3085-7. Meuwis MA, Fillet M, Lutteri L, Marée R, Geurts P, de Seny D, Malaise M, Chapelle JP, Wehenkel L, Belaiche J, Merville MP, Louis E.Proteomics for prediction and characterization of response to infliximab in Crohn's disease: a pilot study. Clin Biochem. 2008 Aug;41(12):960-7. Gisbert JP, Niño P, Cara C, Rodrigo L.Comparative effectiveness of azathioprine in Crohn's disease and ulcerative colitis: prospective, long-term, follow-up study of 394 patients. Aliment Pharmacol Ther. 2008 Jul;28(2):228-38. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, Baert F, Noman M, Vermeire S, Ternant D, Watier H, Paintaud G, Rutgeerts P.Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology. 2008 Jun;134(7):1861-8. Dicksved J, Halfvarson J, Rosenquist M, Järnerot G, Tysk C, Apajalahti J, Engstrand L, Jansson JK.Molecular analysis of the gut microbiota of identical twins with Crohn's disease. ISME J. 2008 Jul;2(7):716-27. Angelberger S, Reinisch W, Dejaco C, Miehsler W, Waldhoer T, Wehkamp J, Lichtenberger C, Schaeffeler E, Vogelsang H, Schwab M, Teml A.NOD2/CARD15 gene variants are linked to failure of antibiotic treatment in perianal fistulating Crohn's disease. Am J Gastroenterol. 2008 May;103(5):1197-202. Tinè F, Rossi F, Sferrazza A, Orlando A, Mocciaro F, Scimeca D, Olivo M, Cottone M.Meta-analysis: remission and response from control arms of randomized trials of biological therapies for active luminal Crohn's disease. Aliment Pharmacol Ther. 2008 Jun;27(12):1210-23. Matsumoto T, Iida M, Motoya S, Haruma K, Suzuki Y, Kobayashi K, Ito H, Miyata M, Kusunoki M, Chiba T, Yamamoto S, Hibi T.Therapeutic efficacy of infliximab on patients with short duration of Crohn's disease: a Japanese multicenter survey. Dis Colon Rectum. 2008 Jun;51(6):916-23. Leiper K, Martin K, Ellis A, Watson AJ, Morris AI, Rhodes JM.Clinical trial: randomized study of clarithromycin versus placebo in active Crohn's disease. Aliment Pharmacol Ther. 2008 Jun;27(12):1233-9. Sokol H, Lay C, Seksik P, Tannock GW.Analysis of bacterial bowel communities of IBD patients: what has it revealed? Inflamm Bowel Dis. 2008 Jun;14(6):858-67. Emanuel PO, Phelps RG.Metastatic Crohn's disease: a histopathologic study of 12 cases. J Cutan Pathol. 2008 May;35(5):457-61. Spehlmann ME, Begun AZ, Burghardt J, Lepage P, Raedler A, Schreiber S.Epidemiology of inflammatory bowel disease in a German twin cohort: results of a nationwide study. Inflamm Bowel Dis. 2008 Jul;14(7):968-76. Kane SV, Reddy D.Hormonal replacement therapy after menopause is protective of disease activity in women with inflammatory bowel disease. Am J Gastroenterol. 2008 May;103(5):1193-6. Ripollés T, Martínez MJ, Barrachina MM.Crohn's disease and color Doppler sonography: response to treatment and its relationship with long-term prognosis. J Clin Ultrasound. 2008 Jun;36(5):267-72. Gal E, Geller A, Fraser G, Levi Z, Niv Y.Assessment and validation of the new capsule endoscopy Crohn's disease activity index (CECDAI). Dig Dis Sci. 2008 Jul;53(7):1933-7. Del Vescovo R, Sansoni I, Caviglia R, Ribolsi M, Perrone G, Leoncini E, Grasso RF, Cicala M, Zobel BB.Dynamic contrast enhanced magnetic resonance imaging of the terminal ileum: differentiation of activity of Crohn's disease. Abdom Imaging. 2008 Jul-Aug;33(4):417-24. Desmond AN, O'Regan K, Curran C, McWilliams S, Fitzgerald T, Maher MM, Shanahan F. Crohn's disease: factors associated with exposure to high levels of diagnostic radiation. Gut. 2008 Apr 29. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, Baert F, Noman M, Vermeire S, Ternant D, Watier H, Paintaud G, Rutgeerts P. Withdrawal of Immunosuppression in Crohn's Disease Treated With Scheduled Infliximab Maintenance: A Randomized Trial. Gastroenterology. 2008 Mar 8. Stasi C, Orlandelli E. Role of the brain-gut axis in the pathophysiology of Crohn's disease. Dig Dis. 2008;26(2):156-66.Benchimol E, Seow Ch, Steinhart A, Griffiths A. Traditional corticosteroids for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2008 Apr 16;(2):CD006792. Reddy D, Murphy SJ, Kane SV, Present DH, Kornbluth AA. Relapses of inflammatory bowel disease during pregnancy: in-hospital management and birth outcomes. m J Gastroenterol. 2008 May;103(5):1203-9.Dicksved J, Halfvarson J, Rosenquist M, Järnerot G, Tysk C, Apajalahti J, Engstrand L, Jansson JK. Molecular analysis of the gut microbiota of identical twins with Crohn's disease. ISME J. 2008 Apr 10. Castiglione F, Bucci L, Pesce G, De Palma GD, Camera L, Cipolletta F, Testa A, Diaferia M, Rispo A. Oral contrast-enhanced sonography for the diagnosis and grading of postsurgical recurrence of Crohn's disease. Inflamm Bowel Dis. 2008 Apr 8. Predicting Relapse in Crohn's Disease: A Biopsychosocial Model. Gut. 2008 Apr 7. Angelberger S, Reinisch W, Dejaco C, Miehsler W, Waldhoer T, Wehkamp J, Lichtenberger C, Schaeffeler E, Vogelsang H, Schwab M, Teml A. NOD2/CARD15 gene variants are linked to failure of antibiotic treatment in perianal fistulating Crohn's disease. Am J Gastroenterol. 2008 May;103(5):1197-202. Colorectal cancer risk in Crohn's disease. World J Gastroenterol. 2008 Mar 28;14(12):1810-1. Tinè F, Rossi F, Sferrazza A, Orlando A, Mocciaro F, Scimeca D, Olivo M, Cottone M. Meta-analysis: remission and response from control arms of randomized trials of biological therapies for active luminal Crohn's disease. Aliment Pharmacol Ther. 2008 Jun;27(12):1210-23. Methotrexate as single therapy in Crohn's disease: is its long-term efficacy limited? Gastroenterol Clin Biol. 2008 Feb;32(2):153-7. Benjamin J, Makharia GK, Ahuja V, Kalaivani M, Joshi YK. Intestinal permeability and its association with the patient and disease characteristics in Crohn's disease. World J Gastroenterol. 2008 Mar 7;14(9):1399-405. Therapeutic Efficacy of Infliximab on Patients with Short Duration of Crohn's Disease: A Japanese Multicenter Survey. Dis Colon Rectum. 2008 Mar 6. Leiper K, Martin K, Ellis A, Watson AJ, Morris AI, Rhodes JM.Clinical trial: randomized study of clarithromycin versus placebo in active Crohn's disease. Aliment Pharmacol Ther. 2008 Jun;27(12):1233-9. Anti-Inflammatory Role of Sympathetic Nerves in Chronic Intestinal Inflammation. Gut. 2008 Feb 28. D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, De Vos M, van Deventer S, Stitt L, Donner A, Vermeire S, Van de Mierop FJ, Coche JC, van der Woude J, Ochsenkühn T, van Bodegraven AA, Van Hootegem PP, Lambrecht GL, Mana F, Rutgeerts P, Feagan BG, Hommes D; Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008 Feb 23;371(9613):660-7.Murphy SJ, Ullman TA, Abreu MT. Gut microbes in Crohn's disease: getting to know you better? Am J Gastroenterol. 2008 Feb;103(2):397-8. Sorrentino D. Role of biologics and other therapies in stricturing Crohn's disease: what have we learnt so far? Digestion. 2008;77(1):38-47.Domènech E, Mañosa M, Navarro M, Masnou H, Garcia-Planella E, Zabana Y, Cabré E, Gassull MA. Long-term methotrexate for Crohn's disease: safety and efficacy in clinical practice. J Clin Gastroenterol. 2008 Apr;42(4):395-9. Rahimi R, Nikfar S, Rahimi F, Elahi B, Derakhshani S, Vafaie M, Abdollahi M. A Meta-Analysis on the Efficacy of Probiotics for Maintenance of Remission and Prevention of Clinical and Endoscopic Relapse in Crohn's Disease. Dig Dis Sci. 2008 Feb 14.Eshuis EJ, Polle SW, Slors JF, Hommes DW, Sprangers MA, Gouma DJ, Bemelman WA. Long-Term Surgical Recurrence, Morbidity, Quality of Life, and Body Image of Laparoscopic-Assisted vs. Open Ileocolic Resection for Crohn's Disease: A Comparative Study. Dis Colon Rectum. 2008 Feb 12. Emanuel PO, Phelps RG. Metastatic Crohn's disease: a histopathologic study of 12 cases. J Cutan Pathol. 2008 May;35(5):457-61.Mottet C, Juillerat P, Pittet V, Gonvers JJ, Froehlich F, Vader JP, Michetti P, Felley C. Pregnancy and breastfeeding in patients with Crohn's disease.Digestion. 2007;76(2):149-60. Epub 2008 Feb 7. Review. Gonvers JJ, Juillerat P, Mottet C, Pittet V, Felley C, Vader JP, Michetti P, Froehlich F. Maintenance of medically induced remission of Crohn's disease. Digestion. 2007;76(2):116-29.Michetti P, Mottet C, Juillerat P, Pittet V, Felley C, Vader JP, Gonvers JJ, Froehlich F. Severe and steroid-resistant Crohn's disease. Digestion. 2007;76(2):99-108. Yip JS, Woodward M, Abreu MT, Sparrow MP. How are Azathioprine and 6-mercaptopurine dosed by gastroenterologists? Results of a survey of clinical practice. Inflamm Bowel Dis. 2008 Apr;14(4):514-8. The use of adalimumab in the management of refractory Crohn's disease. Aliment Pharmacol Ther. 2008 Feb 15;27(4):308-15. Swidsinski A, Loening-Baucke V, Vaneechoutte M, Doerffel Y. Active Crohn's disease and ulcerative colitis can be specifically diagnosed and monitored based on the biostructure of the fecal flora. Inflamm Bowel Dis. 2008 Feb;14(2):147-61.Kasparek MS, Glatzle J, Mueller MH, Schneider A, Koenigsrainer A, Kreis ME. Postoperative complications have little influence on long-term quality of life in Crohn's patients. J Gastrointest Surg. 2008 Mar;12(3):569-76. Schwandner O, Stadler F, Dietl O, Wirsching RP, Fuerst A. Initial experience on efficacy in closure of cryptoglandular and Crohn's transsphincteric fistulas by the use of the anal fistula plug. Int J Colorectal Dis. 2008 Mar;23(3):319-24. Dilation of colonic strictures by intralesional injection of infliximab in patients with Crohn's colitis.Inflamm Bowel Dis. 2008 Feb;14(2):213-6. Review. Lees CW, Maan AK, Hansoti B, Satsangi J, Arnott ID. Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease.Aliment Pharmacol Ther. 2008 Feb 1;27(3):220-7.Rudolph SJ, Weinberg DI, McCabe RP. Long-term durability of Crohn's disease treatment with infliximab. Dig Dis Sci. 2008 Apr;53(4):1033-41. Bartel G, Weiss I, Turetschek K, Schima W, Püspök A, Waldhoer T, Gasche C. Ingested matter affects intestinal lesions in Crohn's disease. Inflamm Bowel Dis. 2008 Mar;14(3):374-82.Headstrom PD, Rulyak SJ, Lee SD. Prevalence of and risk factors for vitamin B(12) deficiency in patients with Crohn's disease. Inflamm Bowel Dis. 2008 Feb;14(2):217-23. Graham DB, Tishon JR, Borum ML. An evaluation of vaginal symptoms in women with Crohn's disease. Dig Dis Sci. 2008 Mar;53(3):765-6.Mokrowiecka A, Gasiorowska A, Malecka-Panas E. pANCA and ASCA in the diagnosis of different subtypes of inflammatory bowel disease. Hepatogastroenterology. 2007 Jul-Aug;54(77):1443-8. Ghoshal UC, Ghoshal U, Singh H, Tiwari S. Anti-Saccharomyces cerevisiae antibody is not useful to differentiate between Crohn's disease and intestinal tuberculosis in India. J Postgrad Med. 2007 Jul-Sep;53(3):166-70. Minderhoud IM, Samsom M, Oldenburg B. What predicts mucosal inflammation in Crohn's disease patients? Inflamm Bowel Dis. 2007 Jul 30; Akobeng A, Thomas A. Enteral nutrition for maintenance of remission in Crohn's disease.Cochrane Database Syst Rev. 2007 Jul 18;(3): Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OO, Hanauer SB, McColm J, Bloomfield R, Sandborn WJ; PRECISE 2 Study Investigators. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007 Jul 19;357(3):239-50. Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S; PRECISE 1 Study Investigators. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007 Jul 19;357(3):228-38. Johnson FR, Ozdemir S, Mansfield C, Hass S, Miller DW, Siegel CA, Sands BE. Crohn's Disease Patients' Risk-Benefit Preferences: Serious Adverse Event Risks Versus Treatment Efficacy.Gastroenterology. 2007 May 3; East JE, Brooker JC, Rutter MD, Saunders BP. A Pilot Study of Intrastricture Steroid Versus Placebo Injection After Balloon Dilatation of Crohn's Strictures. Clin Gastroenterol Hepatol. 2007 Jul 10; Chrissafidou A, Malek M, Musch E. Experimental study on the use of intravenous immunoglobulin (IVIg) in patients with steroid-resistant Crohn's disease. Z Gastroenterol. 2007 Jul;45(7):605-8. Jones JL, Loftus EV Jr. Lymphoma risk in inflammatory bowel disease: Is it the disease or its treatment? Inflamm Bowel Dis. 2007 Jun 28; Katsanos KH, Vermeire S, Christodoulou DK, Riis L, Wolters F, Odes S, Freitas J, Hoie O, Beltrami M, Fornaciari G, Clofent J, Bodini P, Vatn M, Nunes PB, Moum B, Munkholm P, Limonard C, Stockbrugger R, Rutgeerts P, Tsianos EV. Dysplasia and Cancer in Inflammatory Bowel Disease 10 Years after Diagnosis: Results of a Population-Based European Collaborative Follow-Up Study. Digestion. 2007 Jun 26;75(2-3):113-121 Friedman S. Medical therapy and birth outcomes in women with Crohn's disease: what should we tell our patients? Am J Gastroenterol. 2007 Jul;102(7):1414-6. Lorea Baroja M, Kirjavainen PV, Hekmat S, Reid G. Anti-inflammatory effects of probiotic yogurt in inflammatory bowel disease patients. Clin Exp Immunol. 2007 Sep;149(3):470-9. Van Kruiningen HJ, Joossens M, Vermeire S, Joossens S, Debeugny S, Gower-Rousseau C, Cortot A, Colombel JF, Rutgeerts P, Vlietinck R. Familial Crohn's disease in belgium: pedigrees, temporal relationships among cases, and family histories. J Clin Gastroenterol. 2007 Jul;41(6):583-90. Norgard B, Hundborg HH, Jacobsen BA, Nielsen GL, Fonager K. Disease Activity in Pregnant Women With Crohn's Disease and Birth Outcomes: A Regional Danish Cohort Study. Am J Gastroenterol. 2007 Jun 15; Freeman HJ. Application of the Montreal classification for Crohn's disease to a single clinician database of 1015 patients. Can J Gastroenterol. 2007 Jun;21(6):363-6. Casellas F, Rodrigo L, Nino P, Pantiga C, Riestra S, Malagelada JR. Sustained improvement of health-related quality of life in Crohn's disease patients treated with infliximab and azathioprine for 4 years. Inflamm Bowel Dis. 2007 Jun 13; Thoreson R, Cullen JJ. Pathophysiology of inflammatory bowel disease: an overview. Surg Clin North Am. 2007 Jun;87(3):575-85. Review. Keuchel M. Double balloon (push-and-pull) enteroscopy: breakthrough in the management of small intestinal strictures in Crohn's disease? Eur J Gastroenterol Hepatol. 2007 Jul;19(7):523-5. Sun B, Shen R, Cheng S, Zhang C, Zhong J. The role of double-balloon enteroscopy in diagnosis and management of incomplete small-bowel obstruction. Endoscopy. 2007 Jun;39(6):511-5. Steinhart AH, Forbes A, Mills EC, Rodgers-Gray BS, Travis SP. Systematic review: the potential influence of mesalazine formulation on maintenance of remission in Crohn's disease. Aliment Pharmacol Ther. 2007 Jun 15;25(12):1389-99. Buxton MJ, Lacey LA, Feagan BG, Niecko T, Miller DW, Townsend RJ. Mapping from disease-specific measures to utility: an analysis of the relationships between the Inflammatory Bowel Disease Questionnaire and Crohn's Disease Activity Index in Crohn's disease and measures of utility. Value Health. 2007 May-Jun;10(3):214-20. Bernard A, Langille M, Hughes S, Rose C, Leddin D, Veldhuyzen van Zanten S. A Systematic Review of Patient Inflammatory Bowel Disease Information Resources on the World Wide Web. Am J Gastroenterol. 2007 May 19; Dhruva Rao PK, Davies M, Price PE, Torkington J. Crohn's disease: systematic review of assessment of disease severity and its relevance to surgery. Colorectal Dis. 2007 May 17; Torres MI, Lorite P, Lopez-Casado MA, Rios A. A new approach using tissue alkaline phosphatase histochemistry to identify Crohn's disease. Pathol Res Pract. 2007;203(6):485-7. Kaplan GG, Pedersen BV, Andersson RE, Sands BE, Korzenik J, Frisch M. The risk of developing Crohn's disease after an appendectomy: A population-based cohirt study in Sweden and Denmark. Gut. 2007 May 9; Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, Spehlmann ME, Rutgeerts PJ, Tulassay Z, Volfova M, Wolf DC, Hernandez C, Bornstein J, Sandborn WJ; International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology. 2007 May;132(5):1672-83. Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, D'Haens G, Li J, Rosenfeld MR, Kent JD, Pollack PF. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007 Jun 19;146(12):829-38. Henriksen M, Jahnsen J, Lygren I, Aadland E, Schulz T, Vatn MH, Moum B; the Ibsen Study Group. Clinical course in Crohn's disease: results of a five-year population-based follow-up study (the IBSEN study). Scand J Gastroenterol. 2007 May;42(5):602-10. Norgard B, Pedersen L, Christensen LA, Sorensen HT. Therapeutic drug use in women with Crohn's disease and birth outcomes: a Danish nationwide cohort study. Am J Gastroenterol. 2007 Jul;102(7):1406-13. McHugh JB, Appelman HD, McKenna BJ. The diagnostic value of endoscopic terminal ileum biopsies. Am J Gastroenterol. 2007 May;102(5):1084-9. von Roon AC, Reese G, Teare J, Constantinides V, Darzi AW, Tekkis PP. The risk of cancer in patients with Crohn's disease. Dis Colon Rectum. 2007 Jun;50(6):839-55. Review. Cornish J, Tan E, Teare J, Teoh TG, Rai R, Clark SK, Tekkis PP. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut. 2007 Jun;56(6):830-7. Epub 2006 Dec 21. Review.
Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present
DH, Spehlmann ME, Rutgeerts PJ, Tulassay Z, Volfova M,
Wolf DC, Hernandez C, Bornstein J, Sandborn WJ;
International Efficacy of Natalizumab in Crohn's Disease
Response and Remission (ENCORE) Trial Group.
Natalizumab for the Treatment of Active Crohn's Disease:
Results of the ENCORE Trial. Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, D'Haens G, Li J, Rosenfeld MR, Kent JD, Pollack PF. Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab. A Randomized Trial. Ann Intern Med. 2007 Apr 30; Karban A, Eliakim R. Effect of smoking on inflammatory bowel disease: Is it disease or organ specific? World J Gastroenterol. 2007 Apr 21;13(15):2150-2.
Papp M, Norman
GL, Altorjay I, Lakatos PL.
Utility of serological markers in inflammatory bowel
diseases: Gadget or magic?
Nuding S,
Fellermann K, Wehkamp J, Stange EF.
Reduced mucosal antimicrobial activity in Crohn's
disease of the colon. Ferrante M, Henckaerts L, Joossens M, Pierik M, Joossens S, Dotan N, Norman G, Altstock R, Van Steen K, Rutgeerts P, Van Assche G, Vermeire S. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut. 2007 Apr 24; Kuhbacher T, Folsch UR. Practical guidelines for the treatment of inflammatory bowel disease. World J Gastroenterol. 2007 Feb 28;13(8):1149-55. Rodgers AD, Cummins AG. CRP Correlates with Clinical Score in Ulcerative Colitis but Not in Crohn's Disease. Dig Dis Sci. 2007 Apr 11;
Guessous I,
Juillerat P, Pittet V, Froehlich F, Burnand B, Mottet C,
Felley C, Michetti P, Vader JP.
Evaluating appropriateness of treatment for Crohn's
disease: feasibility of an explicit approach. Park CH, Kim JO, Choi MG, Kim KJ, Kim YH, Kim YS, Kim TI, Do JH, Ryu JK, Moon JS, Park SH, Shim KN, Lee KM, Lee IS, Chun HJ. Utility of capsule endoscopy for the classification of Crohn's disease: a multicenter study in Korea. Dig Dis Sci. 2007 Jun;52(6):1405-9. Canavan C, Abrams KR, Mayberry JF. Meta-analysis: mortality in Crohn's disease. Aliment Pharmacol Ther. 2007 Apr 15;25(8):861-70. Bortoli A, Saibeni S, Tatarella M, Prada A, Beretta L, Rivolta R, Politi P, Ravelli P, Imperiali G, Colombo E, Pera A, Daperno M, Carnovali M, de Franchis R, Vecchi M; the Study Group for Inflammatory Bowel Diseases GSMII. Pregnancy before and after the diagnosis of inflammatory bowel diseases: retrospective case-control study. J Gastroenterol Hepatol. 2007 Apr;22(4):542-9. Rutgeerts P, Vermeire S, Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut. 2007 Apr;56(4):453-5. Review. Picco MF. New studies on the role of smoking in inflammatory bowel disease: are we not beating a dead horse? Am J Gastroenterol. 2007 Mar;102(3):598-600.
Hyams J,
Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns
J, Liu G, Travers S, Heuschkel R, Markowitz J, Cohen S,
Winter H, Veereman-Wauters G, Ferry G, Baldassano R;
REACH Study Group.
Induction and maintenance infliximab therapy for the
treatment of moderate-to-severe Crohn's disease in
children.
von Roon AC,
Reese G, Teare J, Constantinides V, Darzi AW, Tekkis PP.
The Risk of Cancer in Patients with Crohn's Disease. Chebli JM, Gaburri PD, De Souza AF, Pinto AL, Chebli LA, Felga GE, Forn CG, Pimentel CF. Long-term results with azathioprine therapy in patients with corticosteroid-dependent Crohn's disease: open-label prospective study. J Gastroenterol Hepatol. 2007 Feb;22(2):268-74.
Smith JP,
Stock H, Bingaman S, Mauger D, Rogosnitzky M, Zagon IS.
Low-dose naltrexone therapy improves active Crohn's
disease. Papi C, Festa V, Leandro G, Moretti A, Tanga M, Koch M, Capurso L. Long-term outcome of Crohn's disease following corticosteroid-induced remission. Am J Gastroenterol. 2007 Apr;102(4):814-9. Jess T, Riis L, Vind I, Winther KV, Borg S, Binder V, Langholz E, Thomsen OO, Munkholm P. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis. 2007 Apr;13(4):481-9. Ng SC, Arebi N, Kamm MA. Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease. Inflamm Bowel Dis. 2007 Feb;13(2):129-34.
Mantzaris GJ, Roussos A,
Kalantzis C, Koilakou S, Raptis N, Kalantzis
N.
How adherent to treatment with azathioprine are patients
with Crohn's disease in long-term remission? Dorn SD, Sandler RS. Inflammatory bowel disease is not a risk factor for cardiovascular disease mortality: results from a systematic review and meta-analysis. Am J Gastroenterol. 2007 Mar;102(3):662-7. Review. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. A meta-analysis of broad-spectrum antibiotic therapy in patients with active Crohn's disease. Clin Ther. 2006 Dec;28(12):1983-8.
Wu F,
Dassopoulos T, Cope L, Maitra A, Brant SR, Harris ML,
Bayless TM, Parmigiani G, Chakravarti S.
Genome-wide gene expression differences in Crohn's
disease and ulcerative colitis from endoscopic pinch
biopsies: Insights into distinctive pathogenesis.
Inflamm Bowel Dis. 2007 Jan 29;
Spoettl T, Hausmann M, Klebl F, Dirmeier A, Klump B, Hoffmann J, Herfarth H, Timmer A, Rogler G. Serum soluble TNF receptor I and II levels correlate with disease activity in IBD patients. Inflamm Bowel Dis. 2007 Jan 26; Macdonald J, McDonald J. Natalizumab for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD006097.
Zachos
M, Tondeur M, Griffiths A.
Enteral nutritional therapy for induction of remission
in Crohn's disease. Abubakar I, Myhill DJ, Hart AR, Lake IR, Harvey I, Rhodes JM, Robinson R, Lobo AJ, Probert CS, Hunter PR. A Case-Control Study of Drinking Water and Dairy Products in Crohn's Disease--Further Investigation of the Possible Role of Mycobacterium avium paratuberculosis. Am J Epidemiol. 2007 Jan 19; Vermeire S, Noman M, van Assche G, Baert F, D'Haens G, Rutgeerts PJ. The effectiviness of concomitant immunosuppressive therapy to suppress formation of antibodies to infliximab in crohn's disease. Gut. 2007 Jan 17; Canavan C, Abrams KR, Hawthorne B, Mayberry JF. Long-term prognosis in Crohn's disease: An epidemiological study of patients diagnosed more than 20 years ago in Cardiff. Aliment Pharmacol Ther. 2007 Jan 1;25(1):59-65. Smith JP, Stock H, Bingaman S, Mauger D, Rogosnitzky M, Zagon IS. Low-Dose Naltrexone Therapy Improves Active Crohn's Disease. Am J Gastroenterol. 2007 Jan 11;
Papi C,
Festa V, Leandro G, Moretti A, Tanga M, Koch M, Capurso
L.
Long-Term Outcome of Crohn's Disease Following
Corticosteroid-Induced Remission. Jess T, Riis L, Vind I, Winther KV, Borg S, Binder V, Langholz E, Thomsen OO, Munkholm P. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: A population-based study from Copenhagen, Denmark. Inflamm Bowel Dis. 2006 Dec 19;
Dassopoulos T, Frangakis C, Cruz-Correa M, Talor MV,
Burek CL, Datta L, Nouvet F, Bayless TM, Brant SR.
Antibodies to Saccharomyces cerevisiae in Crohn's
disease: Higher titers are associated with a greater
frequency of mutant NOD2/CARD15 alleles and with a
higher probability of complicated disease.
Mahid
SS, Minor KS, Stromberg AJ, Galandiuk S.
Active and passive smoking in childhood is related to
the development of inflammatory bowel disease. Mantzaris GJ, Roussos A, Kalantzis C, Koilakou S, Raptis N, Kalantzis N. How adherent to treatment with azathioprine are patients with Crohn's disease in long-term remission? Inflamm Bowel Dis. 2006 Dec 19;
Joossens M, Simoens M, Vermeire S, Bossuyt X, Geboes K,
Rutgeerts P.
Contribution of genetic and environmental factors in the
pathogenesis of Crohn's disease in a large family with
multiple cases. Sands BE, Kozarek R, Spainhour J, Barish CF, Becker S, Goldberg L, Katz S, Goldblum R, Harrigan R, Hilton D, Hanauer SB. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab. Inflamm Bowel Dis. 2007 Jan;13(1):2-11. Masunaga Y, Ohno K, Ogawa R, Hashiguchi M, Echizen H, Ogata H. Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease. Ann Pharmacother. 2007 Jan;41(1):21-8. Girelli CM, Porta P, Malacrida V, Barzaghi F, Rocca F. Clinical outcome of patients examined by capsule endoscopy for suspected small bowel Crohn's disease. Dig Liver Dis. 2007 Feb;39(2):148-54. Korzenik JR. Is Crohn's disease due to defective immunity? Gut. 2007 Jan;56(1):2-5. Makharia GK, Sachdev V, Gupta R, Lal S, Pandey RM. Anti-Saccharomyces cerevisiae antibody does not differentiate between Crohn's disease and intestinal tuberculosis. Dig Dis Sci. 2007 Jan;52(1):33-9. Dorn SD, Sandler RS. Inflammatory Bowel Disease Is Not a Risk Factor for Cardiovascular Disease Mortality: Results from a Systematic Review and Meta-Analysis. Am J Gastroenterol. 2006 Dec 11;
Radford-Smith G, Pandeya N.
Associations between NOD2/CARD15 genotype and phenotype
in Crohn's disease--Are we there yet? World J
Gastroenterol. 2006 Nov 28;12(44):7097-103.
Martinez-Medina M, Aldeguer X, Gonzalez-Huix F, Acero D,
Garcia-Gil LJ.
Abnormal microbiota composition in the ileocolonic
mucosa of Crohn's disease patients as revealed by
polymerase chain reaction-denaturing gradient gel
electrophoresis. Seiderer J, Schnitzler F, Brand S, Staudinger T, Pfennig S, Herrmann K, Hofbauer K, Dambacher J, Tillack C, Sackmann M, Goke B, Lohse P, Ochsenkuhn T. Homozygosity for the CARD15 frameshift mutation 1007fs is predictive of early onset of Crohn's disease with ileal stenosis, entero-enteral fistulas, and frequent need for surgical intervention with high risk of re-stenosis. Scand J Gastroenterol. 2006 Dec;41(12):1421-32. Lerebours E, Gower-Rousseau C, Merle V, Brazier F, Debeugny S, Marti R, Salomez JL, Hellot MF, Dupas JL, Colombel JF, Cortot A, Benichou J. Stressful life events as a risk factor for inflammatory bowel disease onset: A population-based case-control study. Am J Gastroenterol. 2007 Jan;102(1):122-31. Sido B, Seel C, Hochlehnert A, Breitkreutz R, Droge W. Low intestinal glutamine level and low glutaminase activity in Crohn's disease: a rational for glutamine supplementation? Dig Dis Sci. 2006 Dec;51(12):2170-9. May A, Ell C. Push-and-pull enteroscopy using the double-balloon technique/double-balloon enteroscopy. Dig Liver Dis. 2006 Dec;38(12):932-8. Oostenbrug LE, Nolte IM, Oosterom E, van der Steege G, te Meerman GJ, van Dullemen HM, Drenth JP, de Jong DJ, van der Linde K, Jansen PL, Kleibeuker JH. CARD15 in inflammatory bowel disease and Crohn's disease phenotypes: an association study and pooled analysis. Dig Liver Dis. 2006 Nov;38(11):834-45. Esaki M, Matsumoto T, Nakamura S, Yada S, Fujisawa K, Jo Y, Iida M. Factors affecting recurrence in patients with Crohn's disease under nutritional therapy. Dis Colon Rectum. 2006 Oct;49 Suppl 1:S68-74.Ng V, Millard W, Lebrun C, Howard J. Exercise and Crohn's disease: speculations on potential benefits. Can J Gastroenterol. 2006 Oct;20(10):657-60.Rolfe VE, Fortun PJ, Hawkey CJ, Bath-Hextall F. Probiotics for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2006 Oct 18;(4):CD004826. Review.Halfvarson J, Jess T, Magnuson A, Montgomery SM, Orholm M, Tysk C, Binder V, Jarnerot G. Environmental factors in inflammatory bowel disease: a co-twin control study of a Swedish-Danish twin population. Inflamm Bowel Dis. 2006 Oct;12(10):925-33.Steenhagen E, de Roos NM, Bouwman CA, van Laarhoven CJ, van Staveren WA. Sources and severity of self-reported food intolerance after ileal pouch-anal anastomosis. J Am Diet Assoc. 2006 Sep;106(9):1459-62. Review article: the intestinal lumen as a therapeutic target in inflammatory bowel disease. Aliment Pharmacol Ther. 2006 Oct;24 Suppl 3:90-5. Mesenteric fat in Crohn's disease: a pathogenetic hallmark or an innocent bystander? Gut. 2006 Sep 6;Day AS, Whitten KE, Lemberg DA, Clarkson C, Vitug-Sales M, Jackson R, Bohane TD. Exclusive enteral feeding as primary therapy for Crohn's disease in Australian children and adolescents: a feasible and effective approach. J Gastroenterol Hepatol. 2006 Oct;21(10):1609-14. Long-term effectiveness of azathioprine in IBD beyond 4 years: a European multicenter study in 1176 patients. Dig Dis Sci. 2006 Sep;51(9):1516-24.Baichi MM, Arifuddin RM, Mantry PS. What we have learned from 5 cases of permanent capsule retention. Gastrointest Endosc. 2006 Aug;64(2):283-7.Cheifetz AS, Kornbluth AA, Legnani P, Schmelkin I, Brown A, Lichtiger S, Lewis BS. The risk of retention of the capsule endoscope in patients with known or suspected Crohn's disease.Am J Gastroenterol. 2006 Oct;101(10):2218-22. Biagi F, Rondonotti E, Campanella J, Villa F, Bianchi PI, Klersy C, De Franchis R, Corazza GR. Video capsule endoscopy and histology for small-bowel mucosa evaluation: a comparison performed by blinded observers. Clin Gastroenterol Hepatol. 2006 Aug;4(8):998-1003.Jo JY, Byeon JS, Choi KD, Park HW, Lee GH, Myung SJ, Jung HY, Yang SK, Hong WS, Kim JH, Ha HK. Comparison of double balloon enteroscopy and small bowel series for the evaluation of small bowel lesions] Korean J Gastroenterol. 2006 Jul;48(1):25-31. Korean. Natalizumab for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2006 Jul 19;3:CD006097. Review.Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006 Jul 19;3:CD005112. Review.Cheifetz AS, Kornbluth AA, Legnani P, Schmelkin I, Brown A, Lichtiger S, Lewis BS. The Risk of Retention of the Capsule Endoscope in Patients with Known or Suspected Crohn's Disease.Am J Gastroenterol. 2006 Jul 18 Schmidt C, Wittig BM, Moser C, Zeitz M, Stallmach A. Cyclophosphamide pulse therapy followed by azathioprine or methotrexate induces long-term remission in patients with steroid-refractory Crohn's disease. Aliment Pharmacol Ther. 2006 Jul 15;24(2):343-50.Ho GT, Chiam P, Drummond H, Loane J, Arnott ID, Satsangi J. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther. 2006 Jul 15;24(2):319-30.Zilberman L, Maharshak N, Arbel Y, Rogowski O, Rozenblat M, Shapira I, Berliner S, Arber N, Dotan I. Correlated Expression of High-Sensitivity C-Reactive Protein in Relation to Disease Activity in Inflammatory Bowel Disease: Lack of Differences between Crohn's Disease and Ulcerative Colitis. Digestion. 2006 Jul 12;73(4):205-209Biagi F, Rondonotti E, Campanella J, Villa F, Bianchi PI, Klersy C, De Franchis R, Corazza GR. Video capsule endoscopy and histology for small-bowel mucosa evaluation: a comparison performed by blinded observers. Clin Gastroenterol Hepatol. 2006 Aug;4(8):998-1003. A simple biological score for predicting low risk of short-term relapse in Crohn's disease.Inflamm Bowel Dis. 2006 Jul;12(7):551-7. Onercept for moderate-to-severe Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2006 Jul;4(7):888-93. Yang CH, Chen XY, Yang F, Ran ZH, Liu WZ, Xiao SD. [Correlation of C-reactive protein with activity of Crohn's disease] Zhonghua Yi Xue Za Zhi. 2006 May 16;86(18):1253-5. Chinese. Disease outcome of inflammatory bowel disease patients: general outline of a Europe-wide population-based 10-year clinical follow-up study. Scand J Gastroenterol Suppl. 2006 May;(243):46-54. Risk factors for colorectal cancer in Crohn's colitis: a case-control study. Inflamm Bowel Dis. 2006 Jun;12(6):491-6.APDW2004 Chinese IBD Working Group. Retrospective analysis of 515 cases of Crohn's disease hospitalization in China: nationwide study from 1990 to 2003. J Gastroenterol Hepatol. 2006 Jun;21(6):1009-15.Tilney HS, Constantinides VA, Heriot AG, Nicolaou M, Athanasiou T, Ziprin P, Darzi AW, Tekkis PP. Comparison of laparoscopic and open ileocecal resection for Crohn's disease: a metaanalysis.Surg Endosc. 2006 Jul;20(7):1036-44. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006 Jun;55(6):749-53. A meta-analysis of the yield of capsule endoscopy compared to other diagnostic modalities in patients with non-stricturing small bowel Crohn's disease. Am J Gastroenterol. 2006 May;101(5):954-64. Isolated ileal erosions in patients with mildly altered bowel habits. A follow-up study of 28 patients. Am J Clin Pathol. 2006 Jun;125(6):838-46.Chamouard P, Richert Z, Meyer N, Rahmi G, Baumann R. Diagnostic value of C-reactive protein for predicting activity level of Crohn's disease. Clin Gastroenterol Hepatol. 2006 Jul;4(7):882-7.De Bona M, Bellumat A, Cian E, Valiante F, Moschini A, De Boni M. Capsule endoscopy findings in patients with suspected Crohn's disease and biochemical markers of inflammation.Dig Liver Dis. 2006 May;38(5):331-5. Quantitative measurement and visual assessment of ileal Crohn's disease activity by CT enterography: correlation with endoscopic severity and C-reactive protein. Gut. 2006 Apr 28; The Role of PillCam Endoscopy in Crohn's Disease: the European Experience. Gastrointest Endosc Clin N Am. 2006 Apr;16(2):287-97. Leighton JA, Triester SL, Sharma VK. Capsule endoscopy: a meta-analysis for use with obscure gastrointestinal bleeding and Crohn's disease. Gastrointest Endosc Clin N Am. 2006 Apr;16(2):229-50.Lappalainen M, Paavola-Sakki P, Halme L, Turunen U, Helio T, Farkkila M, Kontula K. Screening of tumor necrosis factor receptor-associated factor 6 as a candidate gene for inflammatory bowel disease. Scand J Gastroenterol. 2006 Apr;41(4):424-9. Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's disease.Am J Gastroenterol. 2006 Apr;101(4):793-7. Predicting the Crohn's disease activity index from the Harvey-Bradshaw Index. Inflamm Bowel Dis. 2006 Apr;12(4):304-10. Chamouard P, Richert Z, Meyer N, Rahmi G, Baumann R. Diagnostic Value of C-Reactive Protein for Predicting Activity Level of Crohn's Disease. Clin Gastroenterol Hepatol. 2006 Apr 19; Detection of mycobacteria in Crohn's disease by a broad spectrum polymerase chain reaction. J Formos Med Assoc. 2006 Apr;105(4):290-8. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology. 2006 Apr;130(4):1054-61.Hass DJ, Brensinger CM, Lewis JD, Lichtenstein GR. The impact of increased body mass index on the clinical course of Crohn's disease. Clin Gastroenterol Hepatol. 2006 Apr;4(4):482-8.Prantera C, Lochs H, Campieri M, Scribano ML, Sturniolo GC, Castiglione F, Cottone M. Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharmacol Ther. 2006 Apr 15;23(8):1117-25.Giampaolo B, Giuseppe P, Michele B, Alessandro M, Fabrizio S, Alfonso C. Treatment of active steroid-refractory inflammatory bowel diseases with granulocytapheresis: Our experience with a prospective study. World J Gastroenterol. 2006 Apr 14;12(14):2201-4. Systematic review: the use of mesalazine in inflammatory bowel disease. Aliment Pharmacol Ther. 2006 Apr 1;23(7):841-55 Efficacy of infliximab in Crohn's disease. Results of a retrospective multicenter study with a 15-month follow-up. Gastroenterol Clin Biol. 2006 Feb;30(2):247-52.Zelhof B, Biyani CS, Anathhanam AJ, Pollock B, Browning AJ. Severe penile edema: an unusual presentation of metastatic Crohn disease. Int J Urol. 2006 Feb;13(2):189-91. [The role of smoking as a risk factor in inflammatory bowel diseases: single center study in Korea] Korean J Gastroenterol. 2006 Mar;47(3):198-204. A double-blind clinical trial for treatment of Crohn's disease by oral administration of Alequel, a mixture of autologous colon-extracted proteins: a patient-tailored approach. Am J Gastroenterol. 2006 Mar;101(3):561-8.Gonzalez-Rey E, Varela N, Sheibanie AF, Chorny A, Ganea D, Delgado M. Cortistatin, an antiinflammatory peptide with therapeutic action in inflammatory bowel disease. Proc Natl Acad Sci U S A. 2006 Mar 14;103(11):4228-33.Filippi J, Al-Jaouni R, Wiroth JB, Hebuterne X, Schneider SM. Nutritional deficiencies in patients with Crohn's disease in remission. Inflamm Bowel Dis. 2006 Mar;12(3):185-91.Delaunoit T, Limburg PJ, Goldberg RM, Lymp JF, Loftus EV Jr. Colorectal cancer prognosis among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006 Mar;4(3):335-42.Andoh A, Endo Y, Kushima R, Hata K, Tsujikawa T, Sasaki M, Mekata E, Tani T, Fujiyama Y. A case of Crohn's disease involving the gallbladder. World J Gastroenterol. 2006 Feb 14;12(6):977-8. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc. 2006 Mar;63(3):433-42;Florin TH, Paterson EW, Fowler EV, Radford-Smith GL. Clinically active Crohn's disease in the presence of a low C-reactive protein.Scand J Gastroenterol. 2006 Mar;41(3):306-11. A dose-escalating, placebo-controlled, double-blind, single-dose and multi-dose, safety and tolerability study of fontolizumab, a humanised anti-interferon-gamma antibody, in patients with moderate-to-severe Crohn's disease. Gut. 2006 Feb 21; European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut. 2006 Mar;55 Suppl 1:i36-58. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut. 2006 Mar;55 Suppl 1:i16-35. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006 Mar;55(3):426-31. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006 Feb;130(2):323-33;Kraus TA, Cheifetz A, Toy L, Meddings JB, Mayer L. Evidence for a genetic defect in oral tolerance induction in inflammatory bowel disease. Inflamm Bowel Dis. 2006 Feb;12(2):82-8; Crohn's disease: increased mortality 10 years after diagnosis in a Europe-wide population based cohort. Gut. 2006 Apr;55(4):510-8.Lora FL, Amarante HM, Pisani JC, Borba VV, Kulak CA, Carmes ER. [Bone mineral density evaluation in inflammatory bowel disease patients] Arq Gastroenterol. 2005 Oct-Dec;42(4):201-5. Epub 2006 Jan 19. Portuguese.Lapidus A, Akerlund JE, Einarsson C. Gallbladder bile composition in patients with Crohn 's disease. World J Gastroenterol. 2006 Jan 7;12(1):70-4. Effect of fish oil enriched enteral diet on inflammatory bowel disease tissues in organ culture: differential effects on ulcerative colitis and Crohn's disease. World J Gastroenterol. 2005 Dec 21;11(47):7466-72.Romano C, Cucchiara S, Barabino A, Annese V, Sferlazzas C. Usefulness of omega-3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn's disease: a double-blind, randomized, placebo-controlled study. World J Gastroenterol. 2005 Dec 7;11(45):7118-21.Monkemuller K, Weigt J, Treiber G, Kolfenbach S, Kahl S, Rocken C, Ebert M, Fry LC, Malfertheiner P. Diagnostic and therapeutic impact of double-balloon enteroscopy. Endoscopy. 2006 Jan;38(1):67-72. Outcome of capsule endoscopy in determining indication and route for push-and-pull enteroscopy.Endoscopy. 2006 Jan;38(1):49-58. Heine GD, Hadithi M, Groenen MJ, Kuipers EJ, Jacobs MA, Mulder CJ. Double-balloon enteroscopy: indications, diagnostic yield, and complications in a series of 275 patients with suspected small-bowel disease. Endoscopy. 2006 Jan;38(1):42-8.Shaoul R, Rimar Y, Toubi A, Mogilner J, Polak R, Jaffe M. Crohn's disease and recurrent appendicitis: a case report. World J Gastroenterol. 2005 Nov 21;11(43):6891-3.Meyer AM, Ramzan NN, Heigh RI, Leighton JA. Relapse of inflammatory bowel disease associated with use of nonsteroidal anti-inflammatory drugs. Dig Dis Sci. 2006 Jan;51(1):168-72.Henderson S, Hoffman N, Prince R. A double-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease. Am J Gastroenterol. 2006 Jan;101(1):119-23.Binion DG, Kugathasan S, Dwinell MB. Molecular stratification of Crohn's disease by chemokine receptors: fractalkine receptor polymorphisms define a fibrostenosing ileal subgroup. Am J Gastroenterol. 2006 Jan;101(1):107-9. Increased expression of the chemokine fractalkine in Crohn's disease and association of the fractalkine receptor T280M polymorphism with a fibrostenosing disease Phenotype. Am J Gastroenterol. 2006 Jan;101(1):99-106.Shen B, Fazio VW, Remzi FH, Lashner BA. Clinical approach to diseases of ileal pouch-anal anastomosis. Am J Gastroenterol. 2005 Dec;100(12):2796-807. Review.Casellas F, Vivancos JL, Sampedro M, Malagelada JR. Relevance of the phenotypic characteristics of Crohn's disease in patient perception of health-related quality of life. Am J Gastroenterol. 2005 Dec;100(12):2737-42.Jess T, Gamborg M, Matzen P, Munkholm P, Sorensen TI. Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol. 2005 Dec;100(12):2724-9. Review.Harpaz N, Schiano T, Ruf AE, Shukla D, Tao Y, Fishbein TM, Sauter BV, Gondolesi GE. Early and frequent histological recurrence of Crohn's disease in small intestinal allografts. Transplantation. 2005 Dec 27;80(12):1667-70. PMID: 16378058 [PubMed - indexed forKaffes AJ, Koo JH, Meredith C. Double-balloon enteroscopy in the diagnosis and the management of small-bowel diseases: an initial experience in 40 patients. Gastrointest Endosc. 2006 Jan;63(1):81-6.Farrokhyar F, Marshall JK, Easterbrook B, Irvine EJ. Functional gastrointestinal disorders and mood disorders in patients with inactive inflammatory bowel disease: prevalence and impact on health. Inflamm Bowel Dis. 2006 Jan;12(1):38-46. Budesonide in the treatment of inflammatory bowel disease: the first year of experience in clinical practice. Inflamm Bowel Dis. 2006 Jan;12(1):29-32.Hara AK, Leighton JA, Heigh RI, Sharma VK, Silva AC, De Petris G, Hentz JG, Fleischer DE. Crohn disease of the small bowel: preliminary comparison among CT enterography, capsule endoscopy, small-bowel follow-through, and ileoscopy. Radiology. 2006 Jan;238(1):128-34. Toxicity of infliximab in the course of treatment of Crohn's disease. Expert Opin Drug Saf. 2006 Jan;5(1):9-16. Phenotype at diagnosis predicts recurrence rates in Crohn's disease. Gut. 2005 Dec 16;Florie J, Horsthuis K, Hommes DW, Nio CY, Reitsma JB, van Deventer SJ, Stoker J. Magnetic resonance imaging compared with ileocolonoscopy in evaluating disease severity in Crohn's disease. Clin Gastroenterol Hepatol. 2005 Dec;3(12):1221-8.Schroder O, Blumenstein I, Stein J. Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn's disease: a controlled pilot study. Eur J Gastroenterol Hepatol. 2006 Jan;18(1):11-6.Glas J, Torok HP, Daczo J, Tonenchi L, Folwaczny M, Folwaczny C. The leukocyte count predicts the efficacy of treatment with azathioprine in inflammatory bowel disease. Eur J Med Res. 2005 Dec 7;10(12):535-8.Thomas GA, Rhodes J, Ingram JR. Mechanisms of disease: nicotine--a review of its actions in the context of gastrointestinal disease. Nat Clin Pract Gastroenterol Hepatol. 2005 Nov;2(11):536-44. The anti-Saccharomyces cerevisiae antibody assay in a province-wide practice: accurate in identifying cases of Crohn's disease and predicting inflammatory disease. Can J Gastroenterol. 2005 Dec;19(12):717-21. Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn's disease. J Clin Gastroenterol. 2006 Jan;40(1):55-63.Signorelli C, Villa F, Rondonotti E, Abbiati C, Beccari G, de Franchis R. Sensitivity and specificity of the suspected blood identification system in video capsule enteroscopy. Endoscopy. 2005 Dec;37(12):1170-3.Vermeire S, Van Assche G, Rutgeerts P. The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases.Nat Clin Pract Gastroenterol Hepatol. 2005 Dec;2(12):580-6. Flag in the crossroads: flagellin modulates innate and adaptive immunity. Curr Opin Gastroenterol. 2006 Jan;22(1):8-12. Review. Aleksandra Nielsen A, Nederby Nielsen J, Schmedes A, Brandslund I, Hey H. Saliva Interleukin-6 in patients with inflammatory bowel disease. Scand J Gastroenterol. 2005 Dec;40(12):1444-8.Lee N, Radford-Smith G, Taaffe DR. Bone loss in Crohn's disease: exercise as a potential countermeasure. Inflamm Bowel Dis. 2005 Dec;11(12):1108-18.Moolsintong P, Loftus EV Jr, Chari ST, Egan LJ, Tremaine WJ, Sandborn WJ. Acute pancreatitis in patients with Crohn's disease: clinical features and outcomes. Inflamm Bowel Dis. 2005 Dec;11(12):1080-4. Omega-3 fatty acids inhibit an increase of proinflammatory cytokines in patients with active Crohn's disease compared with omega-6 fatty acids. Aliment Pharmacol Ther. 2005 Dec;22(11-12):1121-8.Domenech E, Hinojosa J, Nos P, Garcia-Planella E, Cabre E, Bernal I, Gassull MA. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated? Aliment Pharmacol Ther. 2005 Dec;22(11-12):1107-13.de Silva AD, Tsironi E, Feakins RM, Rampton DS. Efficacy and tolerability of oral iron therapy in inflammatory bowel disease: a prospective, comparative trial. Aliment Pharmacol Ther. 2005 Dec;22(11-12):1097-105.Bernstein CN, Greenberg H, Boult I, Chubey S, Leblanc C, Ryner L. A prospective comparison study of MRI versus small bowel follow-through in recurrent Crohn's disease. Am J Gastroenterol. 2005 Nov;100(11):2493-502. Crohn's disease patients carrying Nod2/CARD15 gene variants have an increased and early need for first surgery due to stricturing disease and higher rate of surgical recurrence. Ann Surg. 2005 Nov;242(5):693-700. Prevalence and clinical significance of sonographic detection of enlarged regional lymph nodes in Crohn's disease. Scand J Gastroenterol. 2005 Nov;40(11):1328-33. Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci. 2005 Nov;50(11):2191-3.Haskell H, Andrews CW Jr, Reddy SI, Dendrinos K, Farraye FA, Stucchi AF, Becker JM, Odze RD. Pathologic features and clinical significance of "backwash" ileitis in ulcerative colitis. Am J Surg Pathol. 2005 Nov;29(11):1472-81. Increased risk of breast cancer in first-degree relatives of Crohn's disease patients. An IG-IBD study. Dig Liver Dis. 2006 Jan;38(1):18-23. Diagnosis of small bowel Crohn's disease: a prospective comparison of capsule endoscopy with magnetic resonance imaging and fluoroscopic enteroclysis. Gut. 2005 Dec;54(12):1721-7.van Staa TP, Card T, Logan RF, Leufkens HG. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut. 2005 Nov;54(11):1573-8.Kratzer W, Haenle MM, Mason RA, von Tirpitz C, Kaechele V. Prevalence of cholelithiasis in patients with chronic inflammatory bowel disease. World J Gastroenterol. 2005 Oct 21;11(39):6170-5.Ladefoged K, Munck LK, Jorgensen F, Engel P. Skip inflammation of the appendiceal orifice: a prospective endoscopic study. Scand J Gastroenterol. 2005 Oct;40(10):1192-6. Erythema nodosum and pyoderma gangrenosum in 50 patients with Crohn's disease. Can J Gastroenterol. 2005 Sep;19(10):603-6.Yao GX, Wang XR, Jiang ZM, Zhang SY, Ni AP. Role of perioperative parenteral nutrition in severely malnourished patients with Crohn's disease. World J Gastroenterol. 2005 Sep 28;11(36):5732-4.Otley A, Steinhart A, Otley A. Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2005 Oct 19;(4):Rosman AS, Melis M, Fichera A. Metaanalysis of trials comparing laparoscopic and open surgery for Crohn's disease. Surg Endosc. 2005 Oct 17; Infliximab in the treatment of extra-intestinal manifestations of Crohn's disease. Scand J Rheumatol. 2005 Sep-Oct;34(5):387-91. Harty S, Fleming P, Rowland M, Crushell E, McDermott M, Drumm B, Bourke B. A prospective study of the oral manifestations of Crohn's disease. Clin Gastroenterol Hepatol. 2005 Sep;3(9):886-91.Marmo R, Rotondano G, Piscopo R, Bianco MA, Siani A, Catalano O, Cipolletta L. Capsule endoscopy versus enteroclysis in the detection of small-bowel involvement in Crohn's disease: a prospective trial. Clin Gastroenterol Hepatol. 2005 Aug;3(8):772-6.Alves A, Panis Y, Bouhnik Y, Marceau C, Rouach Y, Lavergne-Slove A, Vicaut E, Valleur P. Factors That Predict Conversion in 69 Consecutive Patients Undergoing Laparoscopic Ileocecal Resection for Crohn's Disease: A Prospective Study. Dis Colon Rectum. 2005 Oct 3; Clinical indications of the use of antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies in the evaluation of inflammatory bowel disease at an Academic Medical Center. Inflamm Bowel Dis. 2005 Oct;11(10):898-902. The European experience with double-balloon enteroscopy: indications, methodology, safety, and clinical impact. Gastrointest Endosc. 2005 Oct;62(4):545-50.Dubcenco E, Jeejeebhoy KN, Petroniene R, Tang SJ, Zalev AH, Gardiner GW, Baker JP. Capsule endoscopy findings in patients with established and suspected small-bowel Crohn's disease: correlation with radiologic, endoscopic, and histologic findings.Gastrointest Endosc. 2005 Oct;62(4):538-44. Basu D, Lopez I, Kulkarni A, Sellin JH. Impact of race and ethnicity on inflammatory bowel disease. Am J Gastroenterol. 2005 Oct;100(10):2254-61.Dubinsky MC, Reyes E, Ofman J, Chiou CF, Wade S, Sandborn WJ. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am J Gastroenterol. 2005 Oct;100(10):2239-47.Auslander JN, Lieberman DA, Sonnenberg A. Lack of seasonal variation in the endoscopic diagnoses of Crohn's disease and ulcerative colitis. Am J Gastroenterol. 2005 Oct;100(10):2233-8. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. Aliment Pharmacol Ther. 2005 Oct 1;22(7):613-26.Marmo R, Rotondano G, Piscopo R, Bianco MA, Cipolletta L. Meta-analysis: capsule enteroscopy vs. conventional modalities in diagnosis of small bowel diseases. Aliment Pharmacol Ther. 2005 Oct 1;22(7):595-604.Menachem Y, Avidan B, Lavy A, Lang A, Bardan E, Fidder H, Bar-Meir S, Chowers Y. Increasing the infliximab dose is beneficial in Crohn's disease patients who responded to a lower dose and relapsed. Digestion. 2005;72(2-3):124-8. Serum antibodies in first-degree relatives of patients with IBD: a marker of disease susceptibility? A follow-up pilot-study after 7 years.Digestion. 2005;72(2-3):119-23. Long-term clinical behavior of jejunoileal involvement in Crohn's disease. Can J Gastroenterol. 2005 Sep;19(9):575-8. A survey of Canadian gastroenterologists about the use of methotrexate in patients with Crohn's disease. Can J Gastroenterol. 2005 Sep;19(9):553-8. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005 Sep;19 Suppl A:5-36. Crohn's disease: increased mortality 10 years after diagnosis in a Europe-wide population based cohort. Gut. 2005 Sep 8 Infliximab use in Crohn's disease: impact on health care resources in the UK. Eur J Gastroenterol Hepatol. 2005 Oct;17(10):1047-52. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology. 2005 Sep;129(3):807-18. The relation between NOD2/CARD15 mutations and the prevalence and phenotypic heterogeneity of Crohn's disease: lessons from the Israeli Arab Crohn's disease cohort. Dig Dis Sci. 2005 Sep;50(9):1692-7. Strictureplasty for active Crohn's disease. Int J Colorectal Dis. 2005 Aug 30;:1-6 Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study. Aliment Pharmacol Ther. 2005 Sep 1;22(5):453-61. Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched-pair study. Gut. 2005 Aug 24; van der Hagen SJ, Baeten CG, Soeters PB, Beets-Tan RG, Russel MG, van Gemert WG. Staged mucosal advancement flap for the treatment of complex anal fistulas: pretreatment with noncutting Setons and in case of recurrent multiple abscesses a diverting stoma. Colorectal Dis. 2005 Sep;7(5):513-8.Israeli E, Grotto I, Gilburd B, Balicer RD, Goldin E, Wiik A, Shoenfeld Y. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut. 2005 Sep;54(9):1232-6.Garcia Rodriguez LA, Gonzalez-Perez A, Johansson S, Wallander MA. Risk factors for inflammatory bowel disease in the general population. Aliment Pharmacol Ther. 2005 Aug 15;22(4):309-15. Methotrexate for Crohn's disease: experience in a district general hospital. Eur J Gastroenterol Hepatol. 2005 Sep;17(9):893-8.Sandborn WJ, Lofberg R, Feagan BG, Hanauer SB, Campieri M, Greenberg GR. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol. 2005 Aug;100(8):1780-7.Schwartz DA, White CM, Wise PE, Herline AJ. Use of endoscopic ultrasound to guide combination medical and surgical therapy for patients with Crohn's perianal fistulas. Inflamm Bowel Dis. 2005 Aug;11(8):727-32. Solem CA, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis. 2005 Aug;11(8):707-12.Polle SW, Slors JF, Weverling GJ, Gouma DJ, Hommes DW, Bemelman WA. Recurrence after segmental resection for colonic Crohn's disease. Br J Surg. 2005 Sep;92(9):1143-9.Towers R, Naftali T, Gabay G, Carlebach M, Klein A, Novis B. High levels of glucocorticoid receptors in patients with active Crohn's disease may predict steroid resistance. Clin Exp Immunol. 2005 Aug;141(2):357-62.Tekkis PP, Fazio VW, Remzi F, Heriot AG, Manilich E, Strong SA. Risk factors associated with ileal pouch-related fistula following restorative proctocolectomy. Br J Surg. 2005 Oct;92(10):1270-6.Brown CJ, Maclean AR, Cohen Z, Macrae HM, O'Connor BI, McLeod RS. Crohn's disease and indeterminate colitis and the ileal pouch-anal anastomosis: outcomes and patterns of failure.Dis Colon Rectum. 2005 Aug;48(8):1542-9. Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study. Dig Liver Dis. 2005 Aug;37(8):577-83. Kaufman I, Caspi D, Yeshurun D, Dotan I, Yaron M, Elkayam O. The effect of infliximab on extraintestinal manifestations of Crohn's disease. Rheumatol Int. 2005 Aug;25(6):406-10. Crohn's disease: the cold chain hypothesis.Int J Colorectal Dis. 2005 Jul 30;:1-3 Elbaz G, Fich A, Levy A, Holcberg G, Sheiner E. Inflammatory bowel disease and preterm delivery. Int J Gynaecol Obstet. 2005 Jul 22;
Sturniolo GC, Di Leo V,
Vettorato MG, D'Inca R.
Clinical relevance of small-bowel findings detected by wireless
capsule endoscopy. Newby E, Sawczenko A, Thomas A, Wilson D. Interventions for growth failure in childhood Crohn's disease. Cochrane Database Syst Rev. 2005 Jul 20;(3): Choi KD, Song HJ, Kim JS, Jung HC, Song IS. [Efficacy and safety of treatment with infliximab in Crohn's disease-the experience of single center in Korea Korean J Gastroenterol. 2005 Jul;46(1):48-55. Albert JG, Martiny F, Krummenerl A, Stock K, Lesske J, Gobel CM, Lotterer E, Nietsch HH, Behrmann C, Fleig WE. Diagnosis of small bowel Crohn's disease: a prospective comparison of capsule endoscopy with magnetic resonance imaging and fluoroscopic enteroclysis. Gut. 2005 Jul 14; Persoons P, Vermeire S, Demyttenaere K, Fischler B, Vandenberghe J, Van Oudenhove L, Pierik M, Hlavaty T, Van Assche G, Noman M, Rutgeerts P. The impact of major depressive disorder on the short- and long-term outcome of Crohn's disease treatment with infliximab. Aliment Pharmacol Ther. 2005 Jul 15;22(2):101-10.
Swidsinski A, Weber J,
Loening-Baucke V, Hale LP, Lochs H.
Spatial organization and composition of the mucosal flora in
patients with inflammatory bowel disease. J Clin Microbiol. 2005
Jul;43(7):3380-9. Fraquelli M, Colli A, Casazza G, Paggi S, Colucci A, Massironi S, Duca P, Conte D. Role of US in detection of Crohn disease: meta-analysis. Radiology. 2005 Jul;236(1):95-101. Riis L, Munkholm P, Binder V, Candstat LT, Langholz E. Intra- and interobserver variation in the use of the Vienna classification of Crohn's disease. Inflamm Bowel Dis. 2005 Jul;11(7):657-61. Katsanos KH, Christodoulou DK, Michael M, Ioachim E, Tsianos GV, Agnantis N, Tsianos EV. Inflammatory bowel disease-related dysplasia and cancer: A referral center study in northwestern Greece. Eur J Intern Med. 2005 Jun;16(3):170-175. Hegde N, Gayomali C, Rich MW. Infliximab-induced headache and infliximab-induced meningitis: two ends of the same spectrum? South Med J. 2005 May;98(5):564-6.
Leung R, Jones IT.
Clinical experience with Crohn's disease. Lemann M, Mary JY, Colombel JF, Duclos B, Soule JC, Lerebours E, Modigliani R, Bouhnik Y; Groupe D'Etude Therapeutique des Affections Inflammatoires du Tube Digestif. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology. 2005 Jun;128(7):1812-8.
Garcia-Olmo D, Garcia-Arranz M,
Herreros D, Pascual I, Peiro C, Rodriguez-Montes JA.
A phase I clinical trial of the treatment of Crohn's fistula by
adipose mesenchymal stem cell transplantation. Molnar T, Tiszlavicz L, Gyulai C, Nagy F, Lonovics J. Clinical significance of granuloma in Crohn's disease. World J Gastroenterol. 2005 May 28;11(20):3118-21. Deveaux PG, Kimberling J, Galandiuk S. Crohn's disease: presentation and severity compared between black patients and white patients. Dis Colon Rectum. 2005 Jul;48(7):1404-9. Reimund JM, Arondel Y, Escalin G, Finck G, Baumann R, Duclos B. Immune activation and nutritional status in adult Crohn's disease patients. Dig Liver Dis. 2005 Jun;37(6):424-31.
Aberra FN, Brensinger CM,
Bilker WB, Lichtenstein GR, Lewis JD.
Antibiotic use and the risk of flare of inflammatory bowel disease. Riegler G, Caserta L, Esposito I, De Filippo FR, Bossa F, Esposito P, Russo MI, Carratu R. Worse clinical course of disease in Crohn's patients with previous appendectomy. Eur J Gastroenterol Hepatol. 2005 Jun;17(6):623-7.
Pulimood AB, Peter S,
Ramakrishna B, Chacko A, Jeyamani R, Jeyaseelan L, Kurian G.
Segmental colonoscopic biopsies in the differentiation of ileocolic
tuberculosis from Crohn's disease. Reimund JM, Arondel Y, Escalin G, Finck G, Baumann R, Duclos B. Immune activation and nutritional status in adult Crohn's disease patients. Dig Liver Dis. 2005 Jun;37(6):424-431. Kiran RP, O'brien-Ermlich B, Achkar JP, Fazio VW, Delaney CP. Management of Peristomal Pyoderma Gangrenosum. Dis Colon Rectum. 2005 Mar 22; Hui T, Landers C, Vasiliauskas E, Abreu M, Dubinsky M, Papadakis KA, Price J, Lin YC, Huiying Y, Targan S, Fleshner P. Serologic Responses in Indeterminate Colitis Patients Before Ileal Pouch-Anal Anastomosis May Determine Those at Risk for Continuous Pouch Inflammation. Dis Colon Rectum. 2005 Apr 14; McDonald J, Feagan B, Jewell D, Brynskov J, Stange E, Macdonald J. Cyclosporine for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2005 Apr 18;(2):
Golder
SK, Schreyer AG, Endlicher E, Feuerbach S, Scholmerich J, Kullmann F, Seitz J,
Rogler G, Herfarth H.
Comparison of capsule endoscopy and magnetic resonance (MR) enteroclysis in
suspected small bowel disease. Galvez J, Rodriguez-Cabezas ME, Zarzuelo A. Effects of dietary fiber on inflammatory bowel disease. Mol Nutr Food Res. 2005 Apr 19; Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology. 2005 Apr;128(4):862-9. Rutgeerts P, Van Assche G, Vermeire S, D'Haens G, Baert F, Noman M, Aerden I, De Hertogh G, Geboes K, Hiele M, D'Hoore A, Penninckx F. Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2005 Apr;128(4):856-61. Johnson GJ, Cosnes J, Mansfield JC. Review article: smoking cessation as primary therapy to modify the course of Crohn's disease. Aliment Pharmacol Ther. 2005 Apr 15;21(8):921-31. Mahadevan U, Terdiman JP, Aron J, Jacobsohn S, Turek P. Infliximab and semen quality in men with inflammatory bowel disease. Inflamm Bowel Dis. 2005 Apr;11(4):395-9. Laharie D, Salzmann M, Boubekeur H, Richy F, Amouretti M, Quinton A, Couzigou P, Lamouliatte H, Zerbib F. Predictors of response to infliximab in luminal Crohn's disease. Gastroenterol Clin Biol. 2005 Feb;29(2):145-9. Cheow HK, Voutnis DD, Evans JW, Szczepura KR, Swift EA, Bird NJ, Ruparelia P, Solanki CK, Ballinger JR, Chilvers ER, Middleton SJ, Peters AM. Quantification of disease activity in patients undergoing leucocyte scintigraphy for suspected inflammatory bowel disease. Eur J Nucl Med Mol Imaging. 2005 Mar;32(3):329-337. Stringer EE, Nicholson TJ, Armstrong D. Efficacy of Topical Metronidazole (10 Percent) in the Treatment of Anorectal Crohn's Disease. Dis Colon Rectum. 2005 Mar 22; Mahadevan U, Kane S, Sandborn WJ, Cohen RD, Hanson K, Terdiman JP, Binion DG. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther. 2005 Mar 15;21(6):733-8. Zankel E, Rogler G, Andus T, Reng CM, Scholmerich J, Timmer A. Crohn's disease patient characteristics in a tertiary referral center: comparison with patients from a population-based cohort. Eur J Gastroenterol Hepatol. 2005 Apr;17(4):395-401. Agret F, Cosnes J, Hassani Z, Gornet JM, Gendre JP, Lemann M, Beaugerie L. Impact of pregnancy on the clinical activity of Crohn's disease. Aliment Pharmacol Ther. 2005 Mar 1;21(5):509-13. Langhorst J, Anthonisen IB, Steder-Neukamm U, Ludtke R, Spahn G, Michalsen A, Dobos GJ. Amount of systemic steroid medication is a strong predictor for the use of complementary and alternative medicine in patients with inflammatory bowel disease: results from a German national survey. Inflamm Bowel Dis. 2005 Mar;11(3):287-95. Wells RW, Blennerhassett MG. The increasing prevalence of Crohn's disease in industrialized societies: the price of progress? Can J Gastroenterol. 2005 Feb;19(2):89-95.
Ecker KW, Stallmach A, Loffler J,
Greinwald R, Achenbach U.
Long-term treatment of high intestinal output syndrome with budesonide in
patients with Crohn's disease and ileostomy. Dis Colon Rectum. 2005
Feb;48(2):237-42. Feagan BG, Sandborn WJ, Baker JP, Cominelli F, Sutherland LR, Elson CO, Salzberg BA, Archambault A, Bernstein CN, Lichtenstein GR, Heath PK, Cameron S, Hanauer SB. A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease. Aliment Pharmacol Ther. 2005 Feb 15;21(4):373-84. Hanauer S, Sandborn WJ, Persson A, Persson T. Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial. Aliment Pharmacol Ther. 2005 Feb 15;21(4):363-71. Sakamoto N, Kono S, Wakai K, Fukuda Y, Satomi M, Shimoyama T, Inaba Y, Miyake Y, Sasaki S, Okamoto K, Kobashi G, Washio M, Yokoyama T, Date C, Tanaka H; Epidemiology Group of the Research Committee on Inflammatory Bowel Disease in Japan. Dietary risk factors for inflammatory bowel disease: a multicenter case-control study in Japan. Inflamm Bowel Dis. 2005 Feb;11(2):154-63. Sands BE, Ooi CJ. A survey of methodological variation in the Crohn's disease activity index. Inflamm Bowel Dis. 2005 Feb;11(2):133-8. Guslandi M. Antibiotics for inflammatory bowel disease: do they work? Eur J Gastroenterol Hepatol. 2005 Feb;17(2):145-7.
Ajaj WM, Lauenstein TC, Pelster G, Gerken G, Ruehm
SG, Debatin JF, Goehde SC.
Magnetic resonance colonography for the detection of inflammatory diseases of
the large bowel: quantifying the inflammatory activity.
Schreyer AG, Rath HC, Kikinis R, Volk
M, Scholmerich J, Feuerbach S, Rogler G, Seitz J, Herfarth H.
Comparison of magnetic resonance imaging colonography with conventional
colonoscopy for the assessment of intestinal inflammation in patients with
inflammatory bowel disease: a feasibility study. Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut. 2005 Feb;54(2):237-41. Annese V, Piepoli A, Latiano A, Lombardi G, Napolitano G, Caruso N, Cocchiara E, Accadia L, Perri F, Andriulli A. LA-DRB1 alleles may influence disease phenotype in patients with inflammatory bowel disease: a critical reappraisal with review of the literature. Dis Colon Rectum. 2005 Jan;48(1):57-64; discussion 64-5. Akobeng A, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's Disease. Cochrane Database Syst Rev. 2005 Jan 25;(1):CD003715. Alfadhli A, McDonald J, Feagan B. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst Rev. 2005 Jan 25;(1):CD003459. Regueiro M, Kip KE, Cheung O, Hegazi RA, Plevy S. Cigarette smoking and age at diagnosis of inflammatory bowel disease. Inflamm Bowel Dis. 2005 Jan;11(1):42-7. Gonzalez-Lama Y, Abreu L, Vera MI, Pastrana M, Tabernero S, Revilla J, Duran JG, Escartin P. Long-term oral tacrolimus therapy in refractory to infliximab fistulizing Crohn's disease: a pilot study. Inflamm Bowel Dis. 2005 Jan;11(1):8-15. Etienney I, Bouhnik Y, Gendre JP, Lemann M, Cosnes J, Matuchansky C, Beaugerie L, Modigliani R, Rambaud JC. Crohn's disease over 20 years after diagnosis in a referral population. Gastroenterol Clin Biol. 2004 Dec;28(12):1233-9. Kane S, Lemieux N. The role of breastfeeding in postpartum disease activity in women with inflammatory bowel disease. Am J Gastroenterol. 2005 Jan;100(1):102-5. Baidoo L, Lichtenstein GR. What next after infliximab? Am J Gastroenterol. 2005 Jan;100(1):80-3. Buning C, Molnar T, Nagy F, Lonovics J, Weltrich R, Bochow B, Genschel J, Schmidt H, Lochs H. NOD2/CARD15 gene polymorphism in patients with inflammatory bowel disease: is Hungary different? World J Gastroenterol. 2005 Jan 21;11(3):407-11. Birrenbach T, Bocker U. Inflammatory bowel disease and smoking: a review of epidemiology, pathophysiology, and therapeutic implications. Inflamm Bowel Dis. 2004 Nov;10(6):848-59. Review. Bonner GF, Fakhri A, Vennamaneni SR. A long-term cohort study of nonsteroidal anti-inflammatory drug use and disease activity in outpatients with inflammatory bowel disease. Inflamm Bowel Dis. 2004 Nov;10(6):751-7. Lamireau T, Cezard JP, Dabadie A, Goulet O, Lachaux A, Turck D, Maurage C, Morali A, Sokal E, Belli D, Stoller J, Cadranel S, Ginies JL, Viola S, Huet F, Languepin J, Lenaerts C, Bury F, Sarles J; French-Speaking Group for Pediatric Gastroenterology Nutrition. Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease. Inflamm Bowel Dis. 2004 Nov;10(6):745-50.
Shaoul R, Karban A, Weiss B, Reif S,
Wasserman D, Pacht A, Eliakim R, Wardi J, Shirin H, Wine E, Leshinsky-Silver E,
Levine A.
NOD2/CARD15 mutations and presence of granulomas in pediatric and adult Crohn's
disease. Glazier KD, Palance AL, Griffel LH, Das KM. The ten-year single-center experience with 6-mercaptopurine in the treatment of inflammatory bowel disease. J Clin Gastroenterol. 2005 Jan;39(1):21-6. Economou M, Trikalinos TA, Loizou KT, Tsianos EV, Ioannidis JP. Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a metaanalysis. Am J Gastroenterol. 2004 Dec;99(12):2393-404. Katz JA, Antoni C, Keenan GF, Smith DE, Jacobs SJ, Lichtenstein GR. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol. 2004 Dec;99(12):2385-92. Annese V, Piepoli A, Perri F, Lombardi G, Latiano A, Napolitano G, Corritore G, Vandewalle P, Poulain D, Colombel JF, Andriulli A. Anti-Saccharomyces cerevisiae mannan antibodies in inflammatory bowel disease: comparison of different assays and correlation with clinical features. Aliment Pharmacol Ther. 2004 Nov 15;20(10):1143-52. Klement E, Cohen RV, Boxman J, Joseph A, Reif S. Breastfeeding and risk of inflammatory bowel disease: a systematic review with meta-analysis. Am J Clin Nutr. 2004 Nov;80(5):1342-52. Review. Wehkamp J, Harder J, Weichenthal M, Schwab M, Schaffeler E, Schlee M, Herrlinger KR, Stallmach A, Noack F, Fritz P, Schroder JM, Bevins CL, Fellermann K, Stange EF. NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression. Gut. 2004 Nov;53(11):1658-64. Parente F, Greco S, Molteni M, Anderloni A, Sampietro GM, Danelli PG, Bianco R, Gallus S, Bianchi Porro G. Oral contrast enhanced bowel ultrasonography in the assessment of small intestine Crohn's disease. A prospective comparison with conventional ultrasound, x ray studies, and ileocolonoscopy. Gut. 2004 Nov;53(11):1652-7. Witthoft T, Ludwig D. Effectiveness and tolerability of repeated treatment with infliximab in patients with Crohn's disease: a retrospective data analysis in Germany. Int J Colorectal Dis. 2005 Jan;20(1):18-23. Robotti D, Cammarota T, Debani P, Sarno A, Astegiano M. Activity of Crohn disease: value of Color-Power-Doppler and contrast-enhanced ultrasonography. Abdom Imaging. 2004 Nov-Dec;29(6):648-52. Epub 2004 May 27. Welcker K, Martin A, Kolle P, Siebeck M, Gross M. Increased Intestinal Permeability in Patients with Inflammatory Bowel Disease. Eur J Med Res. 2004 Oct 29;9(10):456-460. Bouzaidi S, Ben Salem M, Mnif N, Ben Hammouda I, Ben Yedder J, Trabelsi S, Moussa A, Jemaa Y, Debbech R, Salem M, Najjar T, Hamza R. [Bone mineral density in patients with Crohn's disease. about 53 cases] Tunis Med. 2004 Aug;82(8):753-9. Weigand K, Wagner-Thiessen E, Stolte M. Esophagitis in an adolescent patient with Crohn's disease after changing treatment from prednisolone to budesonide. Z Gastroenterol. 2004 Oct;42(10):1179-81.
Sapienza MS, Cohen
S, Dimarino AJ.
Treatment of pyoderma gangrenosum with infliximab in Crohn's disease.
Ryan BM, Russel MG, Schurgers L,
Wichers M, Sijbrandij J, Stockbrugger RW, Schoon E.
Effect of antitumour necrosis factor-alpha therapy on bone turnover in patients
with active Crohn's disease: a prospective study. Weersma RK, Peters FT, Oostenbrug LE, van den Berg AP, van Haastert M, Ploeg RJ, Posthumus MD, Homan van der Heide JJ, Jansen PL, van Dullemen HM. Increased incidence of azathioprine-induced pancreatitis in Crohn's disease compared with other diseases. Aliment Pharmacol Ther. 2004 Oct 15;20(8):843-50. Daperno M, D'Haens G, Van Assche G, Baert F, Bulois P, Maunoury V, Sostegni R, Rocca R, Pera A, Gevers A, Mary JY, Colombel JF, Rutgeerts P. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc. 2004 Oct;60(4):505-12. Velayos FS, Sandborn WJ. Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn's disease. Inflamm Bowel Dis. 2004 Sep;10(5):657-60. Herrlinger KR, Borutta A, Meinhardt G, Stange EF, Fellermann K. Fatal staphylococcal sepsis in Crohn's disease after infliximab. Inflamm Bowel Dis. 2004 Sep;10(5):655-6. Leong RW, Lau JY, Sung JJ. The epidemiology and phenotype of Crohn's disease in the Chinese population. Inflamm Bowel Dis. 2004 Sep;10(5):646-51. Winter TA, O'keefe SJ, Callanan M, Marks T. Impaired gastric acid and pancreatic enzyme secretion in patients with Crohn's disease may be a consequenece of a poor nutritional state. Inflamm Bowel Dis. 2004 Sep;10(5):618-25. Di Sabatino A, Ciccocioppo R, Armellini E, Morera R, Ricevuti L, Cazzola P, Fulle I, Corazza GR. Serum bFGF and VEGF correlate respectively with bowel wall thickness and intramural blood flow in Crohn's disease. Inflamm Bowel Dis. 2004 Sep;10(5):573-7. Barmada MM, Brant SR, Nicolae DL, Achkar JP, Panhuysen CI, Bayless TM, Cho JH, Duerr RH. A genome scan in 260 inflammatory bowel disease-affected relative pairs. Inflamm Bowel Dis. 2004 Sep;10(5):513-20. Witthoft T, Ludwig D. Effectiveness and tolerabilityof repeated treatment with infliximab in patients with Crohn's disease: a retrospective data analysis in Germany. Int J Colorectal Dis. 2004 Sep 30; Holtmann MH, Neurath MF. Anti-TNF strategies in stenosing and fistulizing Crohn's disease. Int J Colorectal Dis. 2004 Sep 30; Kratzer W, Foeller T, Kaechele V, Reinshagen M, Tirpitz CV, Haenle MM. [Intestinal wall vascularisation in Crohn's disease] Z Gastroenterol. 2004 Sep;42(9):973-8. Gay G, Delvaux M, Rey JF. The role of video capsule endoscopy in the diagnosis of digestive diseases: a review of current possibilities. Endoscopy. 2004 Oct;36(10):913-20. Sandborn WJ, Hanauer S, Loftus EV Jr, Tremaine WJ, Kane S, Cohen R, Hanson K, Johnson T, Schmitt D, Jeche R. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol. 2004 Oct;99(10):1984-9. Chowers Y, Odes S, Bujanover Y, Eliakim R, Bar Meir S, Avidan B. The month of birth is linked to the risk of Crohn's disease in the Israeli population. Am J Gastroenterol. 2004 Oct;99(10):1974-6. Nos P, Bastida G, Garrigues V, Calvo F, Ponce M, Maroto N, Ponce J. [Factors influencing the decision to administer systemic corticosteroids in Crohn's disease] Gastroenterol Hepatol. 2004 Oct;27(8):444-9. Mow WS, Landers CJ, Steinhart AH, Feagan BG, Croitoru K, Seidman E, Greenberg GR, Targan SR. High-level serum antibodies to bacterial antigens are associated with antibiotic-induced clinical remission in Crohn's disease: a pilot study. Dig Dis Sci. 2004 Aug;49(7-8):1280-6
Hanauer SB, Korelitz BI, Rutgeerts P,
Peppercorn MA, Thisted RA, Cohen RD, Present DH.
Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine,
mesalamine, or placebo: a 2-year trial. Sandborn WJ, Feagan BG, Radford-Smith G, Kovacs A, Enns R, Innes A, Patel J. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Gut. 2004 Oct;53(10):1485-93. Bassi A, Dodd S, Williamson P, Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut. 2004 Oct;53(10):1471-8. Reynisdottir I, Gudbjartsson DF, Johannsson JH, Manolescu I, Kristjansson K, Stefansson K, Gulcher J, Bjornsson S. A genetic contribution to inflammatory bowel disease in Iceland: a genealogic approach. Clin Gastroenterol Hepatol. 2004 Sep;2(9):806-12. Wolters FL, Russel MG, Stockbrugger RW. Systematic review: has disease outcome in Crohn's disease changed during the last four decades? Aliment Pharmacol Ther. 2004 Sep 1;20(5):483-96. Eliakim R, Suissa A, Yassin K, Katz D, Fischer D. Wireless capsule video endoscopy compared to barium follow-through and computerised tomography in patients with suspected Crohn's disease--final report. Dig Liver Dis. 2004 Aug;36(8):519-22. Wedemeyer J, Kirchhoff T, Sellge G, Bachmann O, Lotz J, Galanski M, Manns MP, Gebel MJ, Bleck JS. Transcutaneous perianal sonography: a sensitive method for the detection of perianal inflammatory lesions in Crohn's disease. World J Gastroenterol. 2004 Oct 1;10(19):2859-63. Soon SY, Ansari A, Yaneza M, Raoof S, Hirst J, Sanderson JD. Experience with the use of low-dose methotrexate for inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2004 Sep;16(9):921-6. Masala G, Bagnoli S, Ceroti M, Saieva C, Trallori G, Zanna I, D'Albasio G, Palli D. Divergent patterns of total and cancer mortality in ulcerative colitis and Crohn's disease patients: the Florence IBD study 1978-2001. Gut. 2004 Sep;53(9):1309-13. Zhan J, Xia ZS, Zhong YQ, Zhang SN, Wang LY, Shu H, Zhu ZH. Clinical analysis of primary small intestinal disease: A report of 309 cases. World J Gastroenterol. 2004 Sep 1;10(17):2585-7. Ito H. Novel therapy for Crohn's disease targeting IL-6 signalling. Expert Opin Ther Targets. 2004 Aug;8(4):287-94. Wenzl HH, Reinisch W, Jahnel J, Stockenhuber F, Tilg H, Kirchgatterer A, Petritsch W. Austrian infliximab experience in Crohn's disease: a nationwide cooperative study with long-term follow-up. Eur J Gastroenterol Hepatol. 2004 Aug;16(8):767-73. Nishimoto N, Kishimoto T. Inhibition of IL-6 for the treatment of inflammatory diseases. Curr Opin Pharmacol. 2004 Aug;4(4):386-91. Forcione DG, Rosen MJ, Kisiel JB, Sands BE. Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease. Gut. 2004 Aug;53(8):1117-22. Hawkey CJ. Stem cell transplantation for Crohn's disease. Best Pract Res Clin Haematol. 2004 Jun;17(2):317-25. Greenberg GR. Antibiotics should be used as first-line therapy for Crohn's disease. Inflamm Bowel Dis. 2004 May;10(3):318-20. Fedorak RN, Madsen KL. Probiotics and the management of inflammatory bowel disease. Inflamm Bowel Dis. 2004 May;10(3):286-99. Panagi S, Palka W, Korelitz BI, Taskin M, Lessnau KD. Diffuse alveolar hemorrhage after infliximab treatment of Crohn's disease. Inflamm Bowel Dis. 2004 May;10(3):274-7. Gupta SK, Fitzgerald JF, Croffie JM, Pfefferkorn MD, Molleston JP, Corkins MR. Comparison of serological markers of inflammatory bowel disease with clinical diagnosis in children. Inflamm Bowel Dis. 2004 May;10(3):240-4. Siffiledeen JS, Fedorak RN, Siminoski K, Jen H, Vaudan E, Abraham N, Seinhart H, Greenberg G. Bones and Crohn's: risk factors associated with low bone mineral density in patients with Crohn's disease. Inflamm Bowel Dis. 2004 May;10(3):220-8 Ikeuchi H, Yamamura T, Nakano H, Kosaka T, Shimoyama T, Fukuda Y. Efficacy of nutritional therapy for perforating and non-perforating Crohn's disease. Hepatogastroenterology. 2004 Jul-Aug;51(58):1050-2. Marshall JK, Cawdron R, Zealley I, Riddell RH, Somers S, Irvine EJ. Prospective comparison of small bowel meal with pneumocolon versus ileo-colonoscopy for the diagnosis of ileal Crohn's disease. Am J Gastroenterol. 2004 Jul;99(7):1321-9.
Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, Diamond RH,
Olson A, Bao W, Rutgeerts P.
Incidence and importance of antibody responses to infliximab after maintenance
or episodic treatment in Crohn's disease. Heresbach D, Alexandre JL, Bretagne JF, Cruchant E, Dabadie A, Dartois-Hoguin M, Girardot PM, Jouanolle H, Kerneis J, Le Verger JC, Louvain V, Pennognon L, Richecoeur M, Politis J, Robaszkiewicz M, Seyrig JA, Tron I; ABERMAD. Crohn's disease in the over-60 age group: a population based study. Eur J Gastroenterol Hepatol. 2004 Jul;16(7):657-64. Keller W, Pritsch M, Von Wietersheim J, Scheib P, Osborn W, Balck F, Dilg R, Schmelz-Schumacher E, Doppl W, Jantschek G, Deter HC; The German Study Group on Psychosocial Intervention in Crohn's Disease. Effect of psychotherapy and relaxation on the psychosocial and somatic course of Crohn's disease: main results of the German Prospective Multicenter Psychotherapy Treatment study on Crohn's Disease. J Psychosom Res. 2004 Jun;56(6):687-96. Somasekar A, Alcolado R. Genital condylomata in a patient receiving infliximab for Crohn's disease. Postgrad Med J. 2004 Jun;80(944):358-9. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology. 2004 May;126(6):1620-33. Review. Vermeire S. NOD2/CARD15: relevance in clinical practice. Best Pract Res Clin Gastroenterol. 2004 Jun;18(3):569-75.
Philpott DJ, Viala J.
Towards an understanding of the role of NOD2/CARD15 in the pathogenesis of
Crohn's disease. Cosnes J. Tobacco and IBD: relevance in the understanding of disease mechanisms and clinical practice. Best Pract Res Clin Gastroenterol. 2004 Jun;18(3):481-96. Lee JU, Kim YH, Lee SY, Kim KH, Chung CH, Kim KH, Son HJ, Rhee PL, Kim JJ, Rhee JC. Dose ascites mean more severe Crohn's disease? Korean J Gastroenterol. 2004 May;43(5):304-9.
Vilien M, Dahlerup JF, Munck LK, Norregaard P, Gronbaek K,
Fallingborg J.
Randomized controlled azathioprine withdrawal after more than two years
treatment in Crohn's disease: increased relapse rate the following year. Buning C, Genschel J, Buhner S, Kruger S, Kling K, Dignass A, Baier P, Bochow B, Ockenga J, Schmidt HH, Lochs H. Mutations in the NOD2/CARD15 gene in Crohn's disease are associated with ileocecal resection and are a risk factor for reoperation. Aliment Pharmacol Ther. 2004 May 15;19(10):1073-8. Ljung T, Karlen P, Schmidt D, Hellstrom PM, Lapidus A, Janczewska I, Sjoqvist U, Lofberg R. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut. 2004 Jun;53(6):849-53. Molinie F, Gower-Rousseau C, Yzet T, Merle V, Grandbastien B, Marti R, Lerebours E, Dupas JL, Colombel JF, Salomez JL, Cortot A. Opposite evolution in incidence of Crohn's disease and ulcerative colitis in Northern France (1988-1999). Gut. 2004 Jun;53(6):843-8. Sandborn WJ, Loftus EV. Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease. Gut. 2004 Jun;53(6):780-2. Su C, Lichtenstein GR, Krok K, Brensinger CM, Lewis JD. A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease. Gastroenterology. 2004 May;126(5):1257-69. Review. Danese S, Motte Cd Cde L, Fiocchi C. Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications. Am J Gastroenterol. 2004 May;99(5):938-45. Review. Hanauer SB, Stromberg U. Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol. 2004 May;2(5):379-88. Plevy S. Do serological markers and cytokines determine the indeterminate? J Clin Gastroenterol. 2004 May-Jun;38(5 Suppl):S51-6. Cheifetz A, Itzkowitz S. The diagnosis and treatment of pouchitis in inflammatory bowel disease. J Clin Gastroenterol. 2004 May-Jun;38(5 Suppl):S44-50. Ge ZZ, Hu YB, Xiao SD. Capsule endoscopy in diagnosis of small bowel Crohn's disease. World J Gastroenterol. 2004 May 1;10(9):1349-52. Gourtsoyiannis N, Papanikolaou N, Grammatikakis J, Papamastorakis G, Prassopoulos P, Roussomoustakaki M. Assessment of Crohn's disease activity in the small bowel with MR and conventional enteroclysis: preliminary results. Eur Radiol. 2004 Jun;14(6):1017-24. Pishori T, Dinnewitzer A, Zmora O, Oberwalder M, Hajjar L, Cotman K, Vernava AM 3rd, Efron J, Weiss EG, Nogueras JJ, Wexner SD. Outcome of patients with indeterminate colitis undergoing a double-stapled ileal pouch-anal anastomosis. Dis Colon Rectum. 2004 May;47(5):717-21. Klebl FH, Bataille F, Hofstadter F, Herfarth H, Scholmerich J, Rogler G. Optimising the diagnostic value of anti-Saccharomyces cerevisiae-antibodies (ASCA) in Crohn's disease. Int J Colorectal Dis. 2004 Jul;19(4):319-24. Mardini HE, Kip KE, Wilson JW. Crohn's disease: a two-year prospective study of the association between psychological distress and disease activity.Dig Dis Sci. 2004 Mar;49(3):492-7. Minderhoud IM, Oldenburg B, Wismeijer JA, van Berge Henegouwen GP, Smout AJ. IBS-like symptoms in patients with inflammatory bowel disease in remission; relationships with quality of life and coping behavior. Dig Dis Sci. 2004 Mar;49(3):469-74.Ludvigsson JF, Krantz M, Bodin L, Stenhammar L, Lindquist B. Elemental versus polymeric enteral nutrition in paediatric Crohn's disease: a multicentre randomized controlled trial. Acta Paediatr. 2004 Mar;93(3):327-35.Joos S, Brinkhaus B, Maluche C, Maupai N, Kohnen R, Kraehmer N, Hahn EG, Schuppan D. Acupuncture and Moxibustion in the Treatment of Active Crohn's Disease: A Randomized Controlled Study. Digestion. 2004 Apr 26Schultz M, Timmer A, Herfarth HH, Sartor RB, Vanderhoof JA, Rath HC. Lactobacillus GG in inducing and maintaining remission of Crohn's disease.BMC Gastroenterol. 2004 Mar 15;4(1):5. Moskovitz DN, Bodian C, Chapman ML, Marion JF, Rubin PH, Scherl E, Present DH. The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients. Am J Gastroenterol. 2004 Apr;99(4):656-61. Substance P and other neuropeptides do not induce mediator release in isolated human intestinal mast cells. Neurogastroenterol Motil. 2004 Apr;16(2):185-93.de Jong DJ, Goullet M, Naber TH. Side effects of azathioprine in patients with Crohn's disease. Eur J Gastroenterol Hepatol. 2004 Feb;16(2):207-12.Higuero T, Merle C, Thiefin G, Coussinet S, Jolly D, Diebold MD, Zeitoun P, Cadiot G. Jejunoileal Crohn's disease: a case-control study.Gastroenterol Clin Biol. 2004 Feb;28(2):160-6. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology. 2004 Apr;126(4):989-96; discussion 947. Casellas F, Alcala MJ, Prieto L, Miro JR, Malagelada JR. Assessment of the influence of disease activity on the quality of life of patients with inflammatory bowel disease using a short questionnaire. Am J Gastroenterol. 2004 Mar;99(3):457-61. CARD15 and HLA DRB1 alleles influence susceptibility and disease localization in Crohn's disease. Am J Gastroenterol. 2004 Feb;99(2):306-15.Esters N, Pierik M, van Steen K, Vermeire S, Claessens G, Joossens S, Vlietinck R, Rutgeerts P. Transmission of CARD15 (NOD2) variants within families of patients with inflammatory bowel disease. Am J Gastroenterol. 2004 Feb;99(2):299-305.Biancone L, Tosti C, Geremia A, Fina D, Petruzziello C, Emerenziani S, Pallone F. Rofecoxib and early relapse of inflammatory bowel disease: an open-label trial.Aliment Pharmacol Ther. 2004 Apr 1;19(7):755-64. Walker LJ, Aldhous MC, Drummond HE, Smith BR, Nimmo ER, Arnott ID, Satsangi J. Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease are associated with disease severity but not NOD2/CARD15 mutations. Clin Exp Immunol. 2004 Mar;135(3):490-6. Frequency of NOD2/CARD15 variants in both sporadic and familial cases of Crohn's disease across Italy. An Italian Group for Inflammatory Bowel Disease Study. Dig Liver Dis. 2004 Feb;36(2):121-4. Disappearance of Crohn's ulcers in the terminal ileum after thalidomide therapy. Can J Gastroenterol. 2004 Feb;18(2):101-4. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004 Feb 26;350(9):876-85Schroder O, Blumenstein I, Schulte-Bockholt A, Stein J. Combining infliximab and methotrexate in fistulizing Crohn's disease resistant or intolerant to azathioprine. Aliment Pharmacol Ther. 2004 Feb 1;19(3):295-301.Jess T, Winther KV, Munkholm P, Langholz E, Binder V. Intestinal and extra-intestinal cancer in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Aliment Pharmacol Ther. 2004 Feb 1;19(3):287-93. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology. 2004 Feb;126(2):402-13.Card T, Logan RF, Rodrigues LC, Wheeler JG. Antibiotic use and the development of Crohn's disease. Gut. 2004 Feb;53(2):246-50. Analysis of the therapeutic efficacy of different doses of budesonide in patients with active Crohn's ileocolitis depending on disease activity and localization.Int J Colorectal Dis. 2004 Mar;19(2):147-52. Blanchet E, Beau P. [Efficacy of hydrostatic balloon dilatation of anastomotic Crohn's disease strictures] Gastroenterol Clin Biol. 2003 Dec;27(12):1105-9. French. Oishi Y, Yao T, Matsui T, Ueki T, Sakurai T, Sakaguchi S. Abnormal pancreatic imaging in Crohn's disease: prevalence and clinical features. J Gastroenterol. 2004 Jan;39(1):26-33. Ota Y, Matsui T, Ono H, Uno H, Matake H, Tsuda S, Sakurai T, Yao T. Value of virtual computed tomographic colonography for Crohn's colitis: comparison with endoscopy and barium enema. Abdom Imaging. 2003 Nov-Dec;28(6):778-83. Lomer MC, Kodjabashia K, Hutchinson C, Greenfield SM, Thompson RP, Powell JJ. Intake of dietary iron is low in patients with Crohn's disease: a case-control study. Br J Nutr. 2004 Jan;91(1):141-8. Klebl FH, Bataille F, Hofstadter F, Herfarth H, Scholmerich J, Rogler G. Optimising the diagnostic value of Anti- Saccharomyces cerevisiae-antibodies (ASCA) in Crohn's disease. Int J Colorectal Dis. 2004 Jan 27
Verea MM, Del Pozo J,
Yebra-Pimentel MT, Porta A, Fonseca E.
Psoriasiform eruption induced by infliximab. Schultz H, Csernok E, Herlyn K, Reichel PH, Moosig F, Cornely OA, Fagerhol MK, Gross WL. ANCA against bactericidal/permeability-increasing protein, azurocidin, calprotectin and defensins in rheumatic and infectious diseases: prevalence and clinical associations. Clin Exp Rheumatol. 2003 Nov-Dec;21(6 Suppl 32):S117-20. van Staa TP, Cooper C, Brusse LS, Leufkens H, Javaid MK, Arden NK. Inflammatory bowel disease and the risk of fracture. Gastroenterology. 2003 Dec;125(6):1591-7. Card T, Hubbard R, Logan RF. Mortality in inflammatory bowel disease: a population-based cohort study. Gastroenterology. 2003 Dec;125(6):1583-90. Cabrera-Abreu JC, Davies P, Matek Z, Murphy MS. Performance of blood tests in diagnosis of inflammatory bowel disease in a specialist clinic. Arch Dis Child. 2004 Jan;89(1):69-71. Morini S, Hassan C, Lorenzetti R, Zullo A, Cerro P, Winn S, Giustini M, Taggi F. Long-term outcome of endoscopic pneumatic dilatation in Crohn's disease. Dig Liver Dis. 2003 Dec;35(12):893-7. Saibeni S, Folli C, de Franchis R, Borsi G, Vecchi M. Diagnostic role and clinical correlates of anti-Saccharomyces cerevisiae antibodies (ASCA) and anti-neutrophil cytoplasmic antibodies (p-ANCA) in Italian patients with inflammatory bowel diseases. Dig Liver Dis. 2003 Dec;35(12):862-8. Colombel JF, Loftus EV Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, Zinsmeister AR, Sandborn WJ.The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004 Jan;126(1):19-31. Sandborn WJ. Evidence-based treatment algorithm for mild to moderate Crohn's disease. Am J Gastroenterol. 2003 Dec;98(12 Suppl):S1-5.
Solem CA, Loftus EV, Tremaine
WJ, Sandborn WJ. Venous
thromboembolism in inflammatory bowel disease. Lichtenstein GR, Yan S, Bala M, Hanauer S. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol. 2004 Jan;99(1):91-6. Rasul I, Wilson SR, MacRae H, Irwin S, Greenberg GR. Clinical and radiological responses after infliximab treatment for perianal fistulizing Crohn's disease. Am J Gastroenterol. 2004 Jan;99(1):82-8. Alexakis C, Caruelle JP, Sezeur A, Cosnes J, Gendre JP, Mosnier H, Beaugerie L, Gallot D, Malafosse M, Barritault D, Kern P.Reversal of abnormal collagen production in Crohn's disease intestinal biopsies treated with regenerating agents. Gut. 2004 Jan;53(1):85-90 Freeman HJ. Temporal and geographic evolution of longstanding Crohn's disease over more than 50 years. Can J Gastroenterol. 2003 Dec;17(12):696-700. van den Bergh FA, Kolkman JJ, Russel MG, Vlaskamp RT, Vermes I. [Calprotectin: a fecal marker for diagnosis and follow-up in patients with chronic inflammatory bowel disease] Ned Tijdschr Geneeskd. 2003 Nov 29;147(48):2360-5. Review. Dutch. Sarzi-Puttini P, Ardizzone S, Manzionna G, Atzeni F, Colombo E, Antivalle M, Carrabba M, Bianchi-Porro G. Infliximab-induced lupus in Crohn's disease: a case report. Dig Liver Dis. 2003 Nov;35(11):814-7. Biancone L, Fiori R, Tosti C, Marinetti A, Catarinacci M, De Nigris F, Simonetti G, Pallone F. Virtual colonoscopy compared with conventional colonoscopy for stricturing postoperative recurrence in Crohn's disease. Inflamm Bowel Dis. 2003 Nov;9(6):343-50.
von Tirpitz C, Steder-Neukamm
U, Glas K, Sander S, Ring C, Klaus J, Reinshagen M.
[Osteoporosis in inflammatory bowel disease - results of a survey among members
of the German Crohn's and Ulcerative Colitis Association] Bartram SA, Peaston RT, Rawlings DJ, Francis RM, Thompson NP. A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease. Aliment Pharmacol Ther. 2003 Dec;18(11-12):1121-7. Harrer M, Reinisch W, Dejaco C, Kratzer V, Gmeiner M, Miehsler W, Norman GL, Gangl A, Vogelsang H. Do high serum levels of anti-Saccharomyces cerevisiae antibodies result from a leakiness of the gut barrier in Crohn's disease? Eur J Gastroenterol Hepatol. 2003 Dec;15(12):1281-5. Reffitt DM, Meenan J, Sanderson JD, Jugdaohsingh R, Powell JJ, Thompson RP. Bone density improves with disease remission in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2003 Dec;15(12):1267-73. Jayaprakash A, Creed T, Stewart L, Colton B, Mountford R, Standen G, Probert C. Should we monitor vitamin B(12) levels in patients who have had end-ileostomy for inflammatory bowel disease? Int J Colorectal Dis. 2003 Nov Roblin X, Serre-Debeauvais F, Phelip JM, Bessard G, Bonaz B. Drug interaction between infliximab and azathioprine in patients with Crohn's disease. Aliment Pharmacol Ther. 2003 Nov 1;18(9):917-25. Di Sabatino A, Ciccocioppo R, Luinetti O, Ricevuti L, Morera R, Cifone MG, Solcia E, Corazza GR. Increased enterocyte apoptosis in inflamed areas of Crohn's disease. Dis Colon Rectum. 2003 Nov;46(11):1498-507. Lecomte T, Contou JF, Beaugerie L, Carbonnel F, Cattan S, Gendre JP, Cosnes J. Predictive factors of response of perianal Crohn's disease to azathioprine or 6-mercaptopurine. Dis Colon Rectum. 2003 Nov;46(11):1469-75. Von Tirpitz C, Epp S, Klaus J, Mason R, Hawa G, Brinskelle-Schmal N, Hofbauer LC, Adler G, Kratzer W, Reinshagen M. Effect of systemic glucocorticoid therapy on bone metabolism and the osteoprotegerin system in patients with active Crohn's disease. Eur J Gastroenterol Hepatol. 2003 Nov;15(11):1165-70. Colombel JF, Ricart E, Loftus EV Jr, Tremaine WJ, Young-Fadok T, Dozois EJ, Wolff BG, Devine R, Pemberton JH, Sandborn WJ. Management of Crohn's disease of the ileoanal pouch with infliximab. Am J Gastroenterol. 2003 Oct;98(10):2239-44. Feagan BG, Yan S, Bala M, Bao W, Lichtenstein GR. The effects of infliximab maintenance therapy on health-related quality of life. Am J Gastroenterol. 2003 Oct;98(10):2232-8. Teml A, Kratzer V, Schneider B, Lochs H, Norman GL, Gangl A, Vogelsang H, Reinisch W. Anti-Saccharomyces cerevisiae antibodies: a stable marker for Crohn's disease during steroid and 5-aminosalicylic acid treatment. Am J Gastroenterol. 2003 Oct;98(10):2226-31.
Lachter J, Krausz MM.
Novel use of a plastic overtube facilitates intraoperative enteroscopy in
Crohn's disease.
Ardizzone S, Bollani S,
Manzionna G, Imbesi V, Colombo E, Bianchi Porro G.
Comparison between methotrexate and azathioprine in the treatment of chronic
active Crohn's disease: a randomised, investigator-blind study. Hofer KN. Oral budesonide in the management of Crohn's disease. Ann Pharmacother. 2003 Oct;37(10):1457-64. Herfarth H, Gross V, Andus T, Caesar I, Vogelsang H, Adler G, Malchow H, Petri A, Gierend M, Scholmerich J. Analysis of the therapeutic efficacy of different doses of budesonide in patients with active Crohn's ileocolitis depending on disease activity and localization. Int J Colorectal Dis. 2003 Sep 9 Freeman HJ. Natural history and clinical behavior of Crohn's disease extending beyond two decades. J Clin Gastroenterol. 2003 Sep;37(3):216-9.
Craig RM, Traynor A, Oyama Y,
Burt RK. Hematopoietic stem
cell transplantation for severe Crohn's disease. Bataille F, Klebl F, Rummele P, Straub RH, Wild P, Scholmerich J, Hofstadter F. Histopathological parameters as predictors for the course of Crohn's disease. Virchows Arch. 2003 Oct;443(4):501-7. Epub 2003 Jul 24. Sandborn WJ, Present DH, Isaacs KL, Wolf DC, Greenberg E, Hanauer SB, Feagan BG, Mayer L, Johnson T, Galanko J, Martin C, Sandler RS. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology. 2003 Aug;125(2):380-8. Kreisel W, Potthoff K, Bertz H, Schmitt-Graeff A, Ruf G, Rasenack J, Finke J. Complete remission of Crohn's disease after high-dose cyclophosphamide and autologous stem cell transplantation. Bone Marrow Transplant. 2003 Aug;32(3):337-40. Garcia-Olmo D, Garcia-Arranz M, Garcia LG, Cuellar ES, Blanco IF, Prianes LA, Montes JA, Pinto FL, Marcos DH, Garcia-Sancho L. Autologous stem cell transplantation for treatment of rectovaginal fistula in perianal Crohn's disease: a new cell-based therapy. Int J Colorectal Dis. 2003 Sep;18(5):451-4 Laghi A, Paolantonio P, Iafrate F, Borrelli O, Dito L, Tomei E, Cucchiara S, Passariello R. [MR of the small bowel with a biphasic oral contrast agent (polyethylene glycol): technical aspects and findings in patients affected by Crohn's disease] Radiol Med (Torino). 2003 Jul-Aug;106(1-2):18-27. Italian. Al-Hussaini AA, Machida HM, Butzner JD. Crohn's disease and cheilitis.Can J Gastroenterol. 2003 Jul;17(7):445-7. Bataille F, Klebl F, Rummele P, Straub RH, Wild P, Scholmerich J, Hofstadter F. Histopathological parameters as predictors for the course of Crohn's disease. Virchows Arch. 2003 Jul 24 Bens G, Laharie D, Beylot-Barry M, Vergier B, Noblesse I, Beylot C, Amouretti M. Successful treatment with infliximab and methotrexate of pyostomatitis vegetans associated with Crohn's disease. Br J Dermatol. 2003 Jul;149(1):181-4. Maconi G, Sampietro GM, Parente F, Pompili G, Russo A, Cristaldi M, Arborio G, Ardizzone S, Matacena G, Taschieri AM, Bianchi Porro G. Contrast radiology, computed tomography and ultrasonography in detecting internal fistulas and intra-abdominal abscesses in Crohn's disease: a prospective comparative study. Am J Gastroenterol. 2003 Jul;98(7):1545-55. de Jong DJ, Mannaerts L, van Rossum LG, Corstens FH, Naber AH. Longitudinal study of bone mineral density in patients with Crohn's disease. Dig Dis Sci. 2003 Jul;48(7):1355-9. Ho P, Law WL, Choy C, Chan GS, Chu KW. Granulomatous appendicitis progressing to Crohn's disease with bleeding complication. ANZ J Surg. 2003 Jul;73(7):554-6. Schmidt T, Reinshagen M, Brambs HJ, Adler G, Rieber A, V Tirpitz C, Kratzer W. [Comparison of conventional enteroclysis, intestinal ultrasound and MRI-enteroclysis for determining changes in the small intestine and complications in patients with Crohn's disease] Z Gastroenterol. 2003 Jul;41(7):641-8. German. Vermeire S, Noman M, Van Assche G, Baert F, Van Steen K, Esters N, Joossens S, Bossuyt X, Rutgeerts P. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology. 2003 Jul;125(1):32-9. Ryan WR, Ley C, Allan RN, Keighley MR. Patients with Crohn's disease are unaware of the risks that smoking has on their disease. J Gastrointest Surg. 2003 Jul-Aug;7(5):706-11. Konrad A, Seibold F. Response of cutaneous Crohn's disease to infliximab and methotrexate. Dig Liver Dis. 2003 May;35(5):351-6. Christodoulou D, Katsanos K, Baltayannis G, Tzabouras N, Tsianos EV. A report on efficacy and safety of azathioprine in a group of inflammatory bowel disease patients in northwest Greece. Hepatogastroenterology. 2003 Jul-Aug;50(52):1021-4. Arslan S, Kav T, Besisik F, Kaymakoglu S, Pinarbasi B, Tozun N, Hamzaoglu HO, Duman D, Ulker A, Parlak E, Palabiyikoglu M, Dokmeci A. Clinical outcome of Crohn's disease treated with infliximab.Hepatogastroenterology. 2003 Jul-Aug;50(52):952-6. Bull TJ, McMinn EJ, Sidi-Boumedine K, Skull A, Durkin D, Neild P, Rhodes G, Pickup R, Hermon-Taylor J. Detection and verification of Mycobacterium avium subsp. paratuberculosis in fresh ileocolonic mucosal biopsy specimens from individuals with and without Crohn's disease. J Clin Microbiol. 2003 Jul;41(7):2915-23. Fellermann K, Wehkamp J, Herrlinger KR, Stange EF. Crohn's disease: a defensin deficiency syndrome? Eur J Gastroenterol Hepatol. 2003 Jun;15(6):627-34. Review. Folwaczny C, Glas J, Torok HP. Crohn's disease: an immunodeficiency? Eur J Gastroenterol Hepatol. 2003 Jun;15(6):621-6. Review Candelli M, Papa A, Nista EC, Danese S, Armuzzi A, Bartolozzi F, Tondi P, Ojetti V, Gasbarrini G, Gasbarrini A. Antibodies to Saccharomyces cerevisiae: are they useful in clinical practice? Hepatogastroenterology. 2003 May-Jun;50(51):718-20. Herrlinger KR, Deibert P, Schwab M, Kreisel W, Fischer C, Fellermann K, Stange EF. Remission maintenance by tioguanine in chronic active Crohn's disease. Aliment Pharmacol Ther. 2003 Jun 15;17(12):1459-64. Arnott ID, McNeill G, Satsangi J. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease. Aliment Pharmacol Ther. 2003 Jun 15;17(12):1451-7. Herrerias JM, Caunedo A, Rodriguez-Tellez M, Pellicer F, Herrerias JM Jr. Capsule endoscopy in patients with suspected Crohn's disease and negative endoscopy. Endoscopy. 2003 Jul;35(7):564-8. Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L, Plevy S. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 2003 Jun;98(6):1315-24 Kane SV, Sandborn WJ, Rufo PA, Zholudev A, Boone J, Lyerly D, Camilleri M, Hanauer SB. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol. 2003 Jun;98(6):1309-14. Halfvarson J, Bodin L, Tysk C, Lindberg E, Jarnerot G. Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristics. Gastroenterology. 2003 Jun;124(7):1767-73. Thjodleifsson B, Sigthorsson G, Cariglia N, Reynisdottir I, Gudbjartsson DF, Kristjansson K, Meddings JB, Gudnason V, Wandall JH, Andersen LP, Sherwood R, Kjeld M, Oddsson E, Gudjonsson H, Bjarnason I. Subclinical intestinal inflammation: an inherited abnormality in Crohn's disease relatives? Gastroenterology. 2003 Jun;124(7):1728-37. Zaccagna A, Bertone A, Puiatti P, Picciotto F, Sprujevnik T, Santucci R, Rossini FP. Anti-tumor necrosis factor alpha monoclonal antibody (infliximab) for the treatment of Pyoderma gangrenosum associated with Crohn's disease. Eur J Dermatol. 2003 May-Jun;13(3):258-60. Doerfler OC, Ruppert-Kohlmayr AJ, Reittner P, Hinterleitner T, Petritsch W, Szolar DH. Helical CT of the small bowel with an alternative oral contrast material in patients with Crohn disease. Abdom Imaging. 2003 May-Jun;28(3):313-8. Thomas-Gibson S, Brooker JC, Hayward CM, Shah SG, Williams CB, Saunders BP. Colonoscopic balloon dilation of Crohn's strictures: a review of long-term outcomes. Eur J Gastroenterol Hepatol. 2003 May;15(5):485-8.Ishikawa T, Okamura S, Oshimoto H, Kobayashi R, Mori M. Metronidazole plus ciprofloxacin therapy for active Crohn's disease. Intern Med. 2003 Apr;42(4):318-21. Braun J, Sieper J. Overview of the use of the anti-TNF agent infliximab in chronic inflammatory diseases. Expert Opin Biol Ther. 2003 Feb;3(1):141-68. Clark W, Raftery J, Song F, Barton P, Cummins C, Fry-Smith A, Burls A. Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease. Health Technol Assess. 2003;7(3):1-78. Tubaro E, Belogi L, Mezzadri CM, Bettelli E. Impact on the bowel of amtolmetin guacyl, a new gastroprotective non-steroidal anti-inflammatory drug. Eur J Pharmacol. 2003 Apr 25;467(1-3):173-83.
Markowitz JF. Therapeutic efficacy and safety of 6-mercaptopurine and azathioprine in patients
with Crohn's disease. Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology. 2003 Apr;124(4):917-24. Eliakim R, Fischer D, Suissa A, Yassin K, Katz D, Guttman N, Migdal M. Wireless capsule video endoscopy is a superior diagnostic tool in comparison to barium follow-through and computerized tomography in patients with suspected Crohn's disease. Eur J Gastroenterol Hepatol. 2003 Apr;15(4):363-7. Garcia-Planella E, Domenech E, Esteve-Comas M, Bernal I, Cabre E, Boix J, Gassull MA. Development of antinuclear antibodies and its clinical impact in patients with Crohn's disease treated with chimeric monoclonal anti-TNFalpha antibodies (infliximab). Eur J Gastroenterol Hepatol. 2003 Apr;15(4):351-4.
Schroder O, Stein J. Low dose methotrexate in inflammatory bowel disease: current status
and future directions. Andus T, Gross V, Caesar I, Schulz HJ, Lochs H, Strohm WD, Gierend M, Weber A, Ewe K, Scholmerich J. Replacement of conventional glucocorticoids by oral pH-modified release budesonide in active and inactive Crohn's disease: results of an open, prospective, multicenter trial. Dig Dis Sci. 2003 Feb;48(2):373-8.
Von Tirpitz C, Klaus J, Steinkamp M, Hofbauer LC,
Kratzer W, Mason R, Boehm BO, Adler G, Reinshagen M. Therapy of osteoporosis in patients with Crohn's disease: a randomized study
comparing sodium fluoride and ibandronate.
Hisabe T, Matsui T, Sakurai T, Murakami Y, Tanabe
H, Matake H, Yao T, Kamachi S, Iwashita A.
Anti- Saccharomyces cerevisiae antibodies in Japanese patients with inflammatory bowel
disease: diagnostic accuracy and clinical value. Caprilli R, Cottone M, Tonelli F, Sturniolo G, Castiglione F, Annese V, Papi C, Viscido A, Camma C, Corrao G, Latella G. Two mesalazine regimens in the prevention of the post-operative recurrence of Crohn's disease: a pragmatic, double-blind, randomized controlled trial. Aliment Pharmacol Ther. 2003 Feb 15;17(4):517-23. Fraser AG. Methotrexate: first-line or second-line immunomodulator? Eur J Gastroenterol Hepatol. 2003 Mar;15(3):225-31. McGovern DP, Travis SP. Thiopurine therapy: when to start and when to stop. Eur J Gastroenterol Hepatol. 2003 Mar;15(3):219-23. Picco MF, Bayless TM. Tobacco consumption and disease duration are associated with fistulizing and stricturing behaviors in the first 8 years of Crohn's disease. Am J Gastroenterol. 2003 Feb;98(2):363-8. Aghdassi E, Wendland BE, Steinhart AH, Wolman SL, Jeejeebhoy K, Allard JP. Antioxidant vitamin supplementation in Crohn's disease decreases oxidative stress. a randomized controlled trial. Am J Gastroenterol. 2003 Feb;98(2):348-53. Fireman Z, Mahajna E, Broide E, Shapiro M, Fich L, Sternberg A, Kopelman Y, Scapa E. Diagnosing small bowel Crohn's disease with wireless capsule endoscopy. Gut. 2003 Mar;52(3):390-2. Stallmach A, Wittig BM, Moser C, Fischinger J, Duchmann R, Zeitz M. Safety and efficacy of intravenous pulse cyclophosphamide in acute steroid refractory inflammatory bowel disease. Gut. 2003 Mar;52(3):377-82. Bamba T, Shimoyama T, Sasaki M, Tsujikawa T, Fukuda Y, Koganei K, Hibi T, Iwao Y, Munakata A, Fukuda S, Matsumoto T, Oshitani N, Hiwatashi N, Oriuchi T, Kitahora T, Utsunomiya T, Saitoh Y, Suzuki Y, Nakajima M. Dietary fat attenuates the benefits of an elemental diet in active Crohn's disease: a randomized, controlled trial. Eur J Gastroenterol Hepatol. 2003 Feb;15(2):151-7. Gorard DA. Enteral nutrition in Crohn's disease: fat in the formula. Eur J Gastroenterol Hepatol. 2003 Feb;15(2):115-8. Ganten M, Encke J, Flosdorff P, Gruber-Hoffmann B, Erb G, Hansmann J. [Follow up of Crohn's disease under therapy with hydro-MRI] Radiologe. 2003 Jan;43(1):26-33. German. Hassan C, Cerro P, Zullo A, Spina C, Morini S. Computed tomography enteroclysis in comparison with ileoscopy in patients with Crohn's disease. Int J Colorectal Dis. 2003 Mar;18(2):121-5. Lamps LW, Madhusudhan KT, Havens JM, Greenson JK, Bronner MP, Chiles MC, Dean PJ, Scott MA. Pathogenic Yersinia DNA is detected in bowel and mesenteric lymph nodes from patients with Crohn's disease. Am J Surg Pathol. 2003 Feb;27(2):220-7. Tursi A, Brandimarte G, Giorgetti G, Nasi G. Assessment of orocaecal transit time in different localization of Crohn's disease and its possible influence on clinical response to therapy. Eur J Gastroenterol Hepatol. 2003 Jan;15(1):69-74. Hart AL, Stagg AJ, Kamm MA. Use of probiotics in the treatment of inflammatory bowel disease. J Clin Gastroenterol. 2003 Feb;36(2):111-9. Holtmann M, Wanitschke R, Helisch A, Bartenstein P, Galle PR, Neurath M. [Anti-TNF antibodies in the treatment of inflammatory intestinal stenoses in Crohn's disease] Z Gastroenterol. 2003 Jan;41(1):11-7. German.
Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn's
disease. Rutgeerts P, Lemmens L, Van Assche G, Noman M, Borghini-Fuhrer I, Goedkoop R. Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study. Aliment Pharmacol Ther. 2003 Jan;17(2):185-92. Schwab M, Schaeffeler E, Marx C, Fromm MF, Kaskas B, Metzler J, Stange E, Herfarth H, Schoelmerich J, Gregor M, Walker S, Cascorbi I, Roots I, Brinkmann U, Zanger UM, Eichelbaum M. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology. 2003 Jan;124(1):26-33 Sandborn WJ, Hanauer SB. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am J Gastroenterol. 2002 Dec;97(12):2962-72. Review. Piodi LP, Bardella M, Rocchia C, Cesana BM, Baldassarri A, Quatrini M. Possible protective effect of 5-aminosalicylic acid on Helicobacter pylori infection in patients with inflammatory bowel disease. J Clin Gastroenterol. 2003 Jan;36(1):22-5. Arslan G, Brunborg LA, Froyland L, Brun JG,
Valen M, Berstad A. Effects of duodenal seal oil administration
in patients with inflammatory bowel disease. Lipids. 2002 Oct;37(10):935-40. Ochsenkuhn T, Goke B, Sackmann M. Combining infliximab with 6-mercaptopurine/azathioprine for fistula therapy in Crohn's disease. Am J Gastroenterol. 2002 Aug;97(8):2022-5. de Jong DJ, Corstens FH, Mannaerts L, van Rossum LG, Naber AH. Corticosteroid-induced osteoporosis: does it occur in patients with Crohn's disease Am J Gastroenterol. 2002 Aug;97(8):2011-5. Suenaert P, Bulteel V, Lemmens L, Noman M, Geypens B, Van Assche G, Geboes K, Ceuppens JL, Rutgeerts P. Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am J Gastroenterol. 2002 Aug;97(8):2000-4. Kane SV, Schoenfeld P, Sandborn WJ, Tremaine W, Hofer T, Feagan BG. Systematic review: the effectiveness of budesonide therapy for Crohn's disease. Aliment Pharmacol Ther. 2002 Aug;16(8):1509-17. Infliximab decreases resource use among patients with Crohn's disease. J Clin Gastroenterol. 2002 Aug;35(2):151-6.Kane S, Stone LJ, Ehrenpreis E. Thalidomide as "Salvage" therapy for patients with delayed hypersensitivity response to infliximab: a case series. J Clin Gastroenterol. 2002 Aug;35(2):149-50. Loftus EV Jr, Crowson CS, Sandborn WJ, Tremaine WJ, O'Fallon WM, Melton LJ 3rd. Long-term fracture risk in patients with Crohn's disease: a population-based study in Olmsted County, Minnesota. Gastroenterology. 2002 Aug;123(2):468-75. Tremaine
WJ, Hanauer SB, Katz S, Winston BD, Levine JG, Persson T, Persson A. Budesonide
CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized
placebo-controlled study in the United States. Am J
Gastroenterol. 2002 Jul;97(7):1748-54. Lichtenstein
GR, Bala M, Han C, DeWoody K, Schaible T. Infliximab
improves quality of life in patients with Crohn's disease. Inflamm
Bowel Dis. 2002 Jul;8(4):237-43. Steinhart AH, Feagan BG, Wong CJ, Vandervoort M, Mikolainis S, Croitoru K, Seidman E, Leddin DJ, Bitton A, Drouin E, Cohen A, Greenberg GR. Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. Gastroenterology. 2002 Jul;123(1):33-40. Esters N, Vermeire S, Joossens S, Noman M, Louis E, Belaiche J, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, Poulain D, Bossuyt X, Rutgeerts P. Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease. Am J Gastroenterol. 2002 Jun;97(6):1458-62. Kugathasan
S, Levy MB, Saeian K, Vasilopoulos S, Kim JP, Prajapati D, Emmons J, Martinez A, Kelly KJ,
Binion DG. Infliximab retreatment in adults and children
with Crohn's disease: risk factors for the development of delayed severe systemic
reaction. Am J Gastroenterol. 2002 Jun;97(6):1408-14. Watanabe M, Hasegawa H, Yamamoto S, Hibi T, Kitajima M. Successful application of laparoscopic surgery to the treatment of Crohn's disease with fistulas. Dis Colon Rectum. 2002 Aug;45(8):1057-61.Mueller MH, Kreis ME, Gross ML, Becker HD, Zittel TT, Jehle EC. Anorectal functional disorders in the absence of anorectal inflammation in patients with Crohn's disease. Br J Surg. 2002 Aug;89(8):1027-31. Pikarsky AJ, Gervaz P, Wexner SD. Perianal Crohn disease: a new scoring system to evaluate and predict outcome of surgical intervention. Arch Surg. 2002 Jul;137(7):774-7; discussion 778. Poritz LS, Rowe WA, Koltun WA. Remicade does not abolish the need for surgery in fistulizing Crohn's disease. Dis Colon Rectum. 2002 Jun;45(6):771-5. Dietz DW, Fazio VW, Laureti S, Strong SA, Hull TL, Church J, Remzi FH, Lavery IC, Senagore AJ. Strictureplasty in diffuse Crohn's jejunoileitis: safe and durable. Dis Colon Rectum. 2002 Jun;45(6):764-70. Nakagoe T, Sawai T, Tsuji T, Jibiki MA, Nanashima A, Yamaguchi H, Yasutake T, Ayabe H. Minilaparotomy approach to terminal ileal Crohn's disease. World J Surg. 2002 Jun;26(6):721-5. Vandell AG, DiPiro JT. Low-dosage methotrexate for treatment and maintenance of remission in patients with inflammatory bowel disease. Pharmacotherapy. 2002 May;22(5):613-20. Mahadevan U, Loftus EV Jr, Tremaine WJ, Sandborn WJ. Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am J Gastroenterol. 2002 Apr;97(4):910-4. Allez M, Lemann M, Bonnet J, Cattan P, Jian R, Modigliani R. Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy. Am J Gastroenterol. 2002 Apr;97(4):947-53. Cino M, Greenberg GR. Bone mineral density in Crohn's disease: a longitudinal study of budesonide, prednisone, and nonsteroid therapy.Am J Gastroenterol. 2002 Apr;97(4):915-21. Ben-Ami H, Ginesin Y, Behar DM, Fischer D, Edoute Y, Lavy A. Diagnosis and treatment of urinary tract complications in Crohn's disease: an experience over 15 years. Can J Gastroenterol. 2002 Apr;16(4):225-9. Prajapati DN, Newcomer JR, Emmons J, Abu-Hajir M, Binion DG. Successful treatment of an acute flare of steroid-resistant Crohn's colitis during pregnancy with unfractionated heparin. Inflamm Bowel Dis. 2002 May;8(3):192-5. Campieri M. New steroids and new salicylates in inflammatory bowel disease: a critical appraisal. Gut. 2002 May;50 Suppl 3:III43-6. Review. Sample C, Bailey RJ, Todoruk D, Sadowski D, Gramlich L, Milan M, Cherry R, Ma M, Lalor E, McKaigney J, Sherbaniuk R, Matic K, Switzer C, Fedorak RN. Clinical experience with infliximab for Crohn's disease: the first 100 patients in Edmonton, Alberta. Can J Gastroenterol. 2002 Mar;16(3):165-70. Thomsen OO, Cortot A, Jewell D, Wright JP, Winter T, Veloso FT, Vatn M, Persson T, Pettersson E. Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life. Am J Gastroenterol. 2002 Mar;97(3):649-53. Mishkin D, Boston FM, Blank D, Yalovsky M, Mishkin S The glucose breath test: a diagnostic test for small bowel stricture(s) in Crohn's disease. Dig Dis Sci. 2002 Mar;47(3):489-94. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut. 2002 Apr;50(4):485-9. Hommes DW, van de Heisteeg BH, van der Spek M, Bartelsman JF, van Deventer SJ. Infliximab treatment for Crohn's disease: one-year experience in a Dutch academic hospital. Inflamm Bowel Dis. 2002 Mar;8(2):81-6. Blain
A, Cattan S, Beaugerie L, Carbonnel F, Gendre JP, Cosnes J. Crohn's disease
clinical course and severity in obese patients. Clin Nutr. 2002 Feb;21(1):51-7. Tanaka
M, Masuda T, Yao T, Saito H, Kusumi T, Nagura H, Kudo H. Observer variation of
diagnoses based on simple biopsy criteria differentiating among Crohn's disease,
ulcerative colitis, and other forms of colitis. J Gastroenterol Hepatol. 2001
Dec;16(12):1368-72. Ikeuchi
H, Kusunoki M, Yamamura T, Nishigami T. Crohn's disease associated with gastric
cancer. J Gastroenterol. 2002 Jan;37(1):47-9. Levine
A, Broide E, Stein M, Bujanover Y, Weizman Z, Dinari G, Pacht A, Branski D, Zahavi I.
Evaluation of oral budesonide for treatment of mild and moderate exacerbations of Crohn's
disease in children. J Pediatr. 2002 Jan;140(1):75-80. Shanahan
F. Crohn's disease. Lancet. 2002 Jan 5;359(9300):62-9. Review. Kaser
A, Mairinger T, Vogel W, Tilg H. Infliximab in severe steroid-refractory
ulcerative colitis: a pilot study. Wien Klin Wochenschr. 2001 Dec 17;113(23-24):930-3. van
Bodegraven AA, Sloots CE, Felt-Bersma RJ, Meuwissen SG. Endosonographic evidence
of persistence of Crohn's disease-associated fistulas after infliximab treatment,
irrespective of clinical response. Dis Colon Rectum. 2002 Jan;45(1):39-45; discussion
45-6. Koukoulis
GK, Ke Y, Henley JD, Cummings OW. Detection of pyloric metaplasia may improve the
biopsy diagnosis of Crohn's ileitis. J Clin Gastroenterol. 2002 Feb;34(2):141-3. Metge
CJ, Blanchard JF, Peterson S, Bernstein CN. Use of pharmaceuticals by inflammatory
bowel disease patients: a population-based study. Am J Gastroenterol. 2001
Dec;96(12):3348-55. Ballinger
A. Management of growth retardation in the young patient with Crohn's disease.
Expert Opin Pharmacother. 2002 Jan;3(1):1-7. Salvarani
C, Vlachonikolis IG, van der Heijde DM, Fornaciari G, Macchioni P, Beltrami M, Olivieri I,
Di Gennaro F, Politi P, Stockbrugger RW, Russel MG. Musculoskeletal manifestations
in a population-based cohort of inflammatory bowel disease patients. Scand J
Gastroenterol. 2001 Dec;36(12):1307-13. Vare
PO, Heikius B, Silvennoinen JA, Karttunen R, Niemela SE, Lehtola JK, Karttunen TJ.
Seroprevalence of Helicobacter pylori infection in inflammatory bowel disease: is
Helicobacter pylori infection a protective factor? Scand J Gastroenterol. 2001
Dec;36(12):1295-300. Matsumura
M, Matsui T, Hatakeyama S, Matake H, Uno H, Sakurai T, Yao T, Oishi T, Iwashita A, Fujioka
T. Prevalence of Helicobacter pylori infection and correlation between severity of
upper gastrointestinal lesions and H. pylori infection in Japanese patients with Crohn's
disease. J Gastroenterol. 2001 Nov;36(11):740-7. Agwunobi
AO, Carlson GL, Anderson ID, Irving MH, Scott NA. Mechanisms of intestinal failure
in Crohn's disease. Dis Colon Rectum. 2001 Dec;44(12):1834-7. Goodgame
RW, Kimball K, Akram S, Ike E, Ou CN, Sutton F, Graham D. Randomized controlled
trial of clarithromycin and ethambutol in the treatment of Crohn's disease. Aliment
Pharmacol Ther. 2001 Dec;15(12):1861-6. Ginsburg
PM, Dassopoulos T, Ehrenpreis ED. Thalidomide treatment for refractory Crohn's
disease: a review of the history, pharmacological mechanisms and clinical literature. Ann
Med. 2001 Nov;33(8):516-25. Review. Bonner
GF. Managing the glucocorticoid dependent inflammatory bowel disease patient. Nakamura
RM, Barry M. Serologic markers in inflammatory bowel disease (IBD). Martinez
F, Nos P, Benlloch S, Ponce J. Hidradenitis suppurativa and Crohn's disease:
response to treatment with infliximab. Inflamm Bowel Dis. 2001 Nov;7(4):323-6. Veloso
FT, Ferreira JT, Barros L, Almeida S. Clinical outcome of Crohn's disease:
analysis according to the vienna classification and clinical activity. Inflamm Bowel Dis.
2001 Nov;7(4):306-13. Mansari OE, Parc Y, Lamy P, Parc R, Tiret E, Beaugerie L. Adenocarcinoma complicating Crohn's disease of the duodenum. Eur J Gastroenterol Hepatol. 2001 Oct;13(10):1259-60 Leiper
K, Woolner J, Mullan MM, Parker T, van der Vliet M, Fear S, Rhodes JM, Hunter JO.
A randomised controlled trial of high versus low long chain triglyceride whole protein
feed in active Crohn's disease. Gut. 2001 Dec;49(6):790-4. Louis
E, Collard A, Oger AF, Degroote E, Aboul Nasr El Yafi FA, Belaiche J. Behaviour of
Crohn's disease according to the Vienna classification: changing pattern over the course
of the disease. Gut. 2001 Dec;49(6):777-82. Fraquelli
M, Losco A, Visentin S, Cesana BM, Pometta R, Colli A, Conte D. Gallstone disease
and related risk factors in patients with Crohn disease: analysis of 330 consecutive
cases. Arch Intern Med. 2001 Oct 8;161(18):2201-4. Achkar JP, Shen B. Medical management of postoperative complications of inflammatory bowel disease: pouchitis and Crohn's disease recurrence. Curr Gastroenterol Rep. 2001 Dec;3(6):484-90. Cho
JH. Update on the genetics of inflammatory bowel disease. Curr Gastroenterol Rep.
2001 Dec;3(6):458-63. Assche
GV. Can we influence fibrosis in Crohn's disease? Acta Gastroenterol Belg. 2001
Apr-Jun;64(2):193-6. Sandborn
WJ. Strategies targeting tumor necrosis factor in Crohn's disease. Acta
Gastroenterol Belg. 2001 Apr-Jun;64(2):170-2. Review. Lapidus
A. The changing epidemiology of inflammatory bowel diseases. Acta Gastroenterol
Belg. 2001 Apr-Jun;64(2):155-9. Rajapakse
R, Korelitz BI. Inflammatory Bowel Disease During Pregnancy. Current treatment
options in gastroenterology.. 2001 Jun;4(3):245-251. O'Sullivan
M, O'Morain C. Nutritional Treatments in Inflammatory Bowel Disease. Current
treatment options in gastroenterology.. 2001 Jun;4(3):207-213. Legnani
PE, Kornbluth A. Immunomodulator Therapy in Inflammatory Bowel Disease. Current
treatment options in gastroenterology.. 2001 Jun;4(3):199-205. Zissis
M, Afroudakis A, Galanopoulos G, Palermos L, Boura X, Michopoulos S, Archimandritis A.
B2 microglobulin: is it a reliable marker of activity in inflammatory bowel disease? Am J
Gastroenterol. 2001 Jul;96(7):2177-83. Blam
ME, Stein RB, Lichtenstein GR. Integrating anti-tumor necrosis factor therapy in
inflammatory bowel disease: current and future perspectives. Am J Gastroenterol. 2001
Jul;96(7):1977-97. Review. Srivastava
MD. Immunomodulatory effects of etanercept (TNFR:Fc) and its use in a patient with
Crohn's disease. Res Commun Mol Pathol Pharmacol. 2001 Jul;109(1-2):125-41. Morris
DL, Montgomery SM, Galloway ML, Pounder RE, Wakefield AJ. Inflammatory bowel
disease and laterality: is left handedness a risk? Gut. 2001 Aug;49(2):199-202. Asakura
H, Yao T, Matsui T, Koganei K, Fukushima T, Takazoe M, Hobara R, Nakano H, Okamura S,
Matsueda K, Kashida H, Makiyama K, Hiwatashi N, Kashiwagi K, Hibi T. Efficacy of
treatment with chimeric monoclonal antibody (Infliximab) to tumor necrosis factor-alpha
for Crohn's disease in Japan: evaluation by rapid turnover proteins, and radiologic and
endoscopic findings. J Gastroenterol Hepatol. 2001 Jul;16(7):763-9. Ishaq
S, Green JR. Tolerability of aminosalicylates in inflammatory bowel disease.
BioDrugs. 2001;15(5):339-49. Review. Fornaciari
G, Salvarani C, Beltrami M, Macchioni P, Stockbrugger RW, Russel MG.
Muscoloskeletal manifestations in inflammatory bowel disease. Can J Gastroenterol. 2001
Jun;15(6):399-403. Review. Panaccione
R. Infliximab for the treatment of Crohn's disease: review and indications for
clinical use in Canada. Can J Gastroenterol. 2001 Jun;15(6):371-5. Review. Komatsu
M, Kobayashi D, Saito K, Furuya D, Yagihashi A, Araake H, Tsuji N, Sakamaki S, Niitsu Y,
Watanabe N. Tumor necrosis factor-alpha in serum of patients with inflammatory
bowel disease as measured by a highly sensitive immuno-PCR. Clin Chem.
2001;47(7):1297-301. Hilsden
RJ, Hodgins D, Czechowsky D, Verhoef MJ, Sutherland LR. Attitudes toward smoking
and smoking behaviors of patients with Crohn's disease. Am J Gastroenterol. 2001
Jun;96(6):1849-53. Miehsler
W, Puspok A, Oberhuber T, Vogelsang H. Impact of different therapeutic regimens on
the outcome of patients with Crohn's disease of the upper gastrointestinal tract. Inflamm
Bowel Dis. 2001 May;7(2):99-105. Sturniolo
GC, Di Leo V, Ferronato A, D'Odorico A, D'Inca R. Zinc supplementation tightens
"leaky gut" in Crohn's disease. Inflamm Bowel Dis. 2001 May;7(2):94-8. Arseneau
KO, Stukenborg GJ, Connors AF Jr, Cominelli F. The incidence of lymphoid and
myeloid malignancies among hospitalized Crohn's disease patients. Inflamm Bowel Dis. 2001
May;7(2):106-12. Ahmad
T, Satsangi J, McGovern D, Bunce M, Jewell DP. The genetics of inflammatory bowel
disease. Aliment Pharmacol Ther. 2001 Jun;15(6):731-48. Sandborn
WJ. Transcending conventional therapies: the role of biologic and other novel
therapies. Inflamm Bowel Dis. 2001 May;7 Suppl 1:S9-16. Review. Sninsky
CA. Altering the natural history of Crohn's disease? Inflamm Bowel Dis. 2001 May;7
Suppl 1:S34-9. Review. Lichtenstein
GR. Approach to corticosteroid-dependent and corticosteroid-refractory Crohn's
disease. Inflamm Bowel Dis. 2001 May;7 Suppl 1:S23-9. Review. Cohen
RD. Efficacy and safety of repeated infliximab infusions for Crohn's disease:
1-year clinical experience. Inflamm Bowel Dis. 2001 May;7 Suppl 1:S17-22. Wagtmans
MJ, Verspaget HW, Lamers CB, van Hogezand RA.Gender-related differences in the
clinical course of Crohn's disease. Am J Gastroenterol. 2001 May;96(5):1541-6. Jorgensen J, Ranlov PJ, Bjerrum PJ, Diemer H, Bisgaard K, Elsborg L. Is an increased intestinal permeability a valid predictor of relapse in Crohn disease? Scand J Gastroenterol. 2001 May;36(5):521-7. Verma
S, Holdsworth CD, Giaffer MH. Does adjuvant nutritional support diminish steroid
dependency in Crohn disease? Scand J Gastroenterol. 2001 Apr;36(4):383-8. Simms
L, Steinhart AH. Budesonide for maintenance of remission in Crohn's disease
(Cochrane Review). Cochrane Database Syst Rev. 2001;1:CD002913. Schreiber
S, Campieri M, Colombel JF, van Deventer SJ, Feagan B, Fedorak R, Forbes A, Gassull M,
Gendre JP, van Hogezand RA, Lofberg R, Modigliani R, Pallone F, Petritsch W, Prantera C,
Rampton D, Seibold F, Vatn M, Zeitz M, Rutgeerts P. Use of anti-tumour necrosis
factor agents in inflammatory bowel disease. European guidelines for 2001-2003. Int J
Colorectal Dis. 2001 Feb;16(1):1-11; discussion 12-3. Bernstein
CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases
in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2001
Apr;96(4):1116-22. Hinojosa
J, Nos P, Ramirez JJ, Hoyos M, Moles JR, Ponce J, Berenguer J. Evolutive pattern
in Crohn's disease: a simplified index using clinical parameters predicts obstructive
behaviour. Eur J Gastroenterol Hepatol. 2001 Mar;13(3):245-9. Kapsoritakis
AN, Koukourakis MI, Sfiridaki A, Potamianos SP, Kosmadaki MG, Koutroubakis LE, Kouroumalis
EA. Mean platelet volume: a useful marker of inflammatory bowel disease activity. Ricart
E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Infliximab for Crohn's
disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J
Gastroenterol. 2001 Mar;96(3):722-9. Cosnes
J, Beaugerie L, Carbonnel F, Gendre JP. Smoking cessation and the course of
Crohn's disease: an intervention study. Gastroenterology. 2001 Apr;120(5):1093-9. Tromm
A, May D, Almus E, Voigt E, Greving I, Schwegler U, Griga T. Cutaneous
manifestations in inflammatory bowel disease.Z Gastroenterol. 2001 Feb;39(2):137-44. Mahmud
N, Weir DG. The urban diet and Crohn's disease: is there a relationship? Eur J
Gastroenterol Hepatol. 2001 Feb;13(2):93-5. Austin
AS, Spiller RC.Inflammatory bowel disease, azathioprine and skin cancer: case
report and literature review. Eur J Gastroenterol Hepatol. 2001 Feb;13(2):193-4. Lomer
MC, Harvey RS, Evans SM, Thompson RP, Powell JJ. Efficacy and tolerability of a
low microparticle diet in a double blind, randomized, pilot study in Crohn's disease.Eur J
Gastroenterol Hepatol. 2001 Feb;13(2):101-6. Bernstein
CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory
bowel disease: a population-based study. Cancer. 2001 Feb 15;91(4):854-62. Freeman
HJ. Application of the Vienna Classification for Crohn's disease to a single
clinician database of 877 patients. Can J Gastroenterol. 2001 Feb;15(2):89-93. Robertson
DJ, Sandler RS. Measles virus and Crohn's disease: a critical appraisal of the
current literature. Inflamm Bowel Dis. 2001 Feb;7(1):51-7. Review. Friedman
S, Marion JF, Scherl E, Rubin PH, Present DH. Intravenous cyclosporine in
refractory pyoderma gangrenosum complicating inflammatory bowel disease. Inflamm Bowel
Dis. 2001 Feb;7(1):1-7. Farrokhyar
F, Swarbrick ET, Grace RH, Hellier MD, Gent AE, Irvine EJ. Low mortality in
ulcerative colitis and Crohn's disease in three regional centers in England. Am J
Gastroenterol. 2001 Feb;96(2):501-7. Friedman
S, Rubin PH, Bodian C, Goldstein E, Harpaz N, Present DH. Screening and
surveillance colonoscopy in chronic Crohn's colitis. Gastroenterology. 2001
Mar;120(4):820-6. Laharie
D, Debeugny S, Peeters M, Van Gossum A, Gower-Rousseau C, Belaiche J, Fiasse R, Dupas JL,
Lerebours E, Piotte S, Cortot A, Vermeire S, Grandbastien B, Colombel JF.
Inflammatory bowel disease in spouses and their offspring. Belaiche
J, Desager JP, Horsmans Y, Louis E. Therapeutic drug monitoring of azathioprine
and 6-mercaptopurine metabolites in Crohn disease. Scand J Gastroenterol. 2001
Jan;36(1):71-6. Stein
RB, Lichtenstein GR. Medical therapy for Crohn's disease: the state of the art.
Surg Clin North Am. 2001 Feb;81(1):71-101, viii. Review. Church
JM. Molecular genetics and Crohn's disease. Surg Clin North Am. 2001
Feb;81(1):31-8, vii-viii. Review. Song
HK, Buzby GP. Nutritional support for Crohn's disease. Surg Clin North Am. 2001
Feb;81(1):103-15, viii. Review. Aufses
AH Jr. The history of Crohn's disease. Surg Clin North Am. 2001 Feb;81(1):1-11,
vii. Askling
J, Dickman PW, Karlen P, Brostrom O, Lapidus A, Lofberg R, Ekbom A. Colorectal
cancer rates among first-degree relatives of patients with inflammatory bowel disease: a
population-based cohort study. Lancet. 2001 Jan 27;357(9252):262-6. Cortot
A, Colombel JF, Rutgeerts P, Lauritsen K, Malchow H, Hamling J, Winter T, Van Gossum A,
Persson T, Pettersson E. Switch from systemic steroids to budesonide in steroid
dependent patients with inactive Crohn's disease. Gut. 2001 Feb;48(2):186-90. Am J Gastroenterol 2000 Aug;95(8):1949-54 Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study. Felder JB, Korelitz BI, Rajapakse R, Schwarz S, Horatagis AP, Gleim G Am J Gastroenterol 2000 Jul;95(7):1730-4 Methotrexate in Crohn’s disease: long-term efficacy and toxicity. Lemann M, Zenjari T, Bouhnik Y, Cosnes J, Mesnard B, Rambaud JC, Modigliani R, Cortot A, Colombel JF N Engl J Med 2000 Jun 1;342(22):1633-7 A preliminary study of growth hormone therapy for Crohn’s disease. Slonim AE, Bulone L, Damore MB, Goldberg T, Wingertzahn MA, McKinley MJ N Engl J Med 2000 Jun 1;342(22):1627-32 A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group Investigators. Feagan BG, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, Greenberg GR, Koval J, Wong CJ, Hopkins M, Hanauer SB, McDonald JW Chir Ital 2000 Mar-Apr;52(2):155-64 Treatment of perianal Crohn’s disease Tersigni R, Alessandroni L, Kohn A, Speziale G Am J Gastroenterol 2000 May;95(5):1139-46 Medical therapy to reduce postoperative Crohn’s disease recurrence. Achkar JP, Hanauer SB Drugs 2000 Apr;59(4):929-56 Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn’s disease. Clemett D, Markham A Cochrane Database Syst Rev 2000;(2):CD000545 Azathioprine or 6-mercaptopurine for inducing remission of Crohn’s disease. Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C Cochrane Database Syst Rev 2000;(2):CD000301 Corticosteroids for maintaining remission of Crohn’s disease. Steinhart AH, Ewe K, Griffiths AM, Modigliani R, Thomsen OO Cochrane Database Syst Rev 2000;(2):CD000299 Anti-tuberculous therapy for maintaining remission of Crohn’s disease. Borgaonkar M, MacIntosh D, Fardy J, Simms L Cochrane Database Syst Rev 2000;(2):CD000067 Azathioprine for maintaining remission of Crohn’s disease. Pearson DC, May GR, Fick G, Sutherland LR J Clin Gastroenterol 2000 Apr;30(3):294-8 Azathioprine and 6-mercaptopurine for the treatment of perianal Crohn’s disease in children. Jeshion WC, Larsen KL, Jawad AF, Piccoli DA, Verma R, Maller ES, Baldassano RN Scand J Gastroenterol 2000 Mar;35(3):281-6 Simple mucosal biopsy criteria differentiating among Crohn disease, ulcerative colitis, and other forms of colitis: measurement of validity. Tanaka M, Saito H, Fukuda S, Sasaki Y, Munakata A, Kudo H Am J Gastroenterol 2000 Apr;95(4):1021-6 Crohn’s disease, pregnancy, and birth weight. Moser MA, Okun NB, Mayes DC, Bailey RJ Br J Surg 2000 Apr;87(4):398-404 Smoking and disease recurrence after operation for Crohn’s disease. Yamamoto T, Keighley MR Dig Dis Sci 2000 Feb;45(2):378-84 Microsatellite instability is uncommon in intestinal mucosa of patients with Crohn’s disease. Noffsinger A, Kretschmer S, Belli J, Fogt F, Fenoglio-Preiser C Cancer Causes Control 2000 Feb;11(2):145-50 Crohn’s disease and cancer risk (Denmark). Mellemkjaer L, Johansen C, Gridley G, Linet MS, Kjaer SK, Olsen JH Am J Gastroenterol 2000 Mar;95(3):725-9 A meta-analysis of antimycobacterial therapy for Crohn’s disease. Borgaonkar MR, MacIntosh DG, Fardy JM Digestion 2000;61(2):121-8 Clinical patterns of Crohn’s disease in Greece: a follow-up study of 155 cases. Triantafillidis JK, Emmanouilidis A, Manousos O, Nicolakis D, Kogevinas M Inflamm Bowel Dis 2000 Feb;6(1):8-15 A simple classification of Crohn’s disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Gasche C, Scholmerich J, Brynskov J, D’Haens G, Hanauer SB, Irvine EJ, Jewell DP, Rachmilewitz D, Sachar DB, Sandborn WJ, Sutherland LR Ugeskr Laeger 2000 Jan 17;162(3):323-6 Azathioprine treatment of Crohn disease. [Article in Danish] Thomsen MK, Vilien M, Gerner CU Gastroenterology 2000 Feb;118(2):264-73 Published erratum appears in Gastroenterology 2000 Jul;119(1):280 Prophylaxis of postoperative relapse in Crohn’s disease with mesalamine: European Cooperative Crohn’s Disease Study VI. Lochs H, Mayer M, Fleig WE, Mortensen PB, Bauer P, Genser D, Petritsch W, Raithel M, Hoffmann R, Gross V, Plauth M, Staun M, Nesje LB Int J Colorectal Dis 1999 Nov;14(4-5):224-6 Operative and environmental risk factors for recurrence of Crohn’s disease. Moskovitz D, McLeod RS, Greenberg GR, Cohen Z Am J Gastroenterol 2000 Jan;95(1):177-82 Impact of surgery for Crohn’s disease on health-related quality of life. Casellas F, Lopez-Vivancos J, Badia X, Vilaseca J, Malagelada JR Ann Surg 2000 Jan;231(1):38-45 Risk factors for surgery and postoperative recurrence in Crohn’s disease. Bernell O, Lapidus A, Hellers G Z Gastroenterol 1999 Nov;37(11):1085-91 Efficacy of azathioprine in the treatment of chronic active Crohn’s disease: prospective one-year follow-up study. German Imurek Study Group. Ludwig D, Stange EF Aliment Pharmacol Ther 1999 Sep;13 Suppl 4:16-22; discussion 38 Review article: safety of infliximab in clinical trials. Hanauer SB Ital J Gastroenterol Hepatol 1999 Aug-Sep;31(6):519-20 Infliximab (Remicade), a new biological treatment for Crohn’s disease. D’Haens GR Am J Gastroenterol 1999 Nov;94(11):3274-8 Perianal Crohn’s disease and pregnancy: role of the mode of delivery. Ilnyckyji A, Blanchard JF, Rawsthorne P, Bernstein CN Zentralbl Chir 1999;124 Suppl 2:42-4 Conservative therapy of fistulas of the anorectal area in Crohn disease [Article in German] Peitz U, Brucks U, Malfertheiner P Am J Gastroenterol 1999 Oct;94(10):2956-60 Intestinal permeability test as a predictor of clinical course in Crohn’s disease. D’Inca R, Di Leo V, Corrao G, Martines D, D’Odorico A, Mestriner C, Venturi C, ongo G, Sturniolo GC Am J Gastroenterol 1999 Oct;94(10):2942-50 Mesenteric blood flow is related to disease activity and risk of relapse in Crohn’s disease: a prospective follow-up study. Ludwig D, Wiener S, Bruning A, Schwarting K, Jantschek G, Stange EF Eur J Gastroenterol Hepatol 1999 Mar;11(3):277-82 Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn’s disease: a multicentre randomized placebo-controlled trial. German Budesonide Study Group. Ewe K, Bottger T, Buhr HJ, Ecker KW, Otto HF Med Klin 1999 Feb 15;94 Suppl 1:22-5 Clinical effects of 5-aminosalicylic acid preparations in Crohn disease. [Article in German] Fleig WE Drugs 1999 Mar;57(3):383-408 Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn’s disease. Prakash A, Markham A Ital J Gastroenterol Hepatol 1998 Dec;30(6):602-6 Use of antibiotics in the treatment of active Crohn’s disease: experience with metronidazole and ciprofloxacin. Prantera C, Berto E, Scribano ML, Falasco G Gastroenterology 1999 Mar;116(3):521-6 Mesalamine in the treatment of mild to moderate active Crohn’s ileitis: results of a randomized, multicenter trial. Prantera C, Cottone M, Pallone F, Annese V, Franze A, Cerutti R, Bianchi Porro G J Clin Gastroenterol 1998 Sep;27(2):129-33 Crohn’s disease in the elderly: a comparison with young adults. Wagtmans MJ, Verspaget HW, Lamers CB, van Hogezand RA Inflamm Bowel Dis 1998 Feb;4(1):29-39 The role of the fecal stream in Crohn’s disease: an historical and analytic review. Janowitz HD, Croen EC, Sachar DB Harefuah 1997 Jan 15;132(2):86-8, 151 Is Crohn’s disease different in the elderly? [Article in Hebrew] Pappo I, Zamir O, Freund HR |
||
